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Erythrocytes are good candidates of lipid-based biomarker studies due to 
various innate properties that they possess. They serve as valuable biomarkers 
in the prognosis and diagnosis of diseases as they are easily obtainable 
through a non-invasive manner. However, the success of biomarker 
development is often limited by the lack of investigation on variability 
involved. As a consequence, investigators today are unable to truly discern if a 
signature biomarker is indeed a metabolic end point or in fact brought about 
by the inherent contribution of technical and biological variations.  
 
In this thesis, targeted mass spectrometry was employed to analyze a 
comprehensive coverage of more than 160 phospholipids, sphingolipids and 
sterols species in the erythrocyte membrane. Strong emphasis was placed in 
meeting the criteria of pre-analytical and analytical precision set by the FDA 
(Food and Drug Administration) to ensure all findings were of biological 
significances and not attributed by technical variations. Following which, lipid 
profiling of the erythrocyte membrane was conducted in a homogenous group 
of healthy volunteers to understand the biological variation in the erythrocytes 
lipidome. No added benefit was found in using fasting blood samples when 
examining the erythrocyte lipids. In order to facilitate the identification of 
reliable biomarkers, demonstration of a novel approach in applying knowledge 
of biological variation in a form of an index was shown. The indexes revealed 
that majority of the erythrocyte membrane lipids were suitable for use in a 
population-based study. Moreover, information on the required number of 
 x 
samples to provide a good estimate of an individual’s homeostatic mean was 
also derived from the index.  
 
The framework of applying valuable insights of biological variation was also 
demonstrated in biomarker development of the erythrocyte lipidome for the 
diagnosis of schizophrenia. Through the indexes of the elucidated lipid 
signature, determination of which lipids were suitable as monitoring (state) or 
diagnostic (trait) biomarkers was allowed. Insights provided by the indexes 
were shown to be exceptionally useful. Thus, future plans of extending these 
studies to other biological fluid and lipid species are impending.  
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1.1.1 Diversity of lipids 
Lipidomics is one of the sub-disciplines in metabolomics [1] and has currently 
received increasing attention as a research area [2]. This field of research 
allows the characterization and extensive listing of various lipid classes with 
hundreds of distinct molecular lipid species present in a biological sample [3, 
4]. An abundant amount of lipids are found in the biological system and they 
constitute around 50% of the mass of most eukaryotic cell membranes [5]. 
Being highly diverse in nature, lipids are divided into eight main categories 
namely fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol 
lipids, prenol lipids, saccharolipids, and polyketides [6, 7]. In just the major 
classes, a conservative theoretical estimate of close to 200,000 of them are 
thought to be present [8]. Despite their numerical dominance, lipids were once 
made to take the back seat in the field of research as they were thought to act 
just as membrane components or as energy storage [2]. Realization that these 
molecules do have other diverse physiological functions rekindled research 
interests. They include functions such as the controlling of transcription and 
translation, signal transduction, cell-cell interactions and acting as biological 
messengers [1, 2, 9].  
 
1.1.2 Advancement in lipidomics technology 
The study of lipids can be accomplished through current chromatographic and 
mass spectrometric techniques. In the past, lipid profiling was hampered by 
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analytical limitations [1]. Traditionally, lipidomics approaches, such as thin 
layer chromatography (TLC) and metabolic labeling, do not allow the 
distinction of individual molecular lipid species. Furthermore, these 
techniques lack sensitivity and require large amount of samples along with 
laborious sample preparation [4, 10]. As a result, most investigators focused 
mainly on defined lipids such as cholesterol [11], neglecting the examination 
of other less abundant lipid species. Today, this is no longer the case. With 
advancement and development in mass spectrometry (MS), comprehensive 
analyses of various lipid species can be readily accomplished through a 
plethora of different analytical techniques [2]. 
 
Most notably, the advent of soft ionization techniques, such as matrix-assisted 
laser desorption/ionization (MALDI), electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI), has made detection of lipids 
possible [2, 12-14]. The development of ESI, in particular, is the core 
technology of lipidomics study. This technique allows non-volatile and high 
mass lipids such as phospholipids, sphingolipids and glycerolipids to be 
effectively analyzed, devoid of any chemical derivatization and minimal 
fragmentation, thus allowing easy analytical interpretation of a lipid mixture 
[2]. Moreover, the ease of coupling lipid eluent from a liquid chromatography 
(LC) experiment to the mass spectrometer has also made ESI the most 
frequently applied ionization technique in lipidomics analysis [2].  
 
Various applications in lipidomics study of different biological samples have 
been reported using ESI-MS or ESI-MS/MS [15-18]. Generally, the most 
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efficient analysis of lipid mixtures using ESI-MS or ESI-MS/MS is via direct-
infusion into the mass spectrometer [2, 10]. Direct-infusion ESI-MS studies in 
lipidomics are categorized into shotgun lipidomics [19] and targeted 
lipidomics [20]. In shotgun lipidomics, high throughput analysis of different 
lipid species can be performed directly from lipid extracts of biological 
samples without chromatographic separation prior to detection [19, 21-23]. 
This is based on intra-source separation where different lipid classes exhibit 
differential ionization efficiency depending on their inherent electrical 
propensities [23, 24]. Each class of lipid is thus resolved in the ionization 
source while individual species can be further characterized by MS and/or 
tandem MS [19]. Due to its speed, capacity for automation and sensitivity in 
quantification of a large group of lipids, shotgun lipidomics is thus highly 
practiced by many [2, 24, 25]. Undeniably, one can acquire ions from 
hundreds of different lipids in just one scan in shotgun lipidomics. However, 
as the mass spectrometer can only tolerate a certain level of complexity, the 
sheer number of lipids that is detected at one time limits the dynamic range of 
the lipids, especially towards the low abundant species [24, 26]. As a result, 
isobaric lipid species are indistinguishable without additional characterization 
by MS and/or tandem MS. This is when targeted lipidomics comes in useful as 
it focuses on selectively monitoring a group of lipid molecules using precursor 
ion scan (PreIS) and/or neutral loss scan (NLS) of their characteristic 
functional groups. By only targeting the measurement of a smaller group of 
lipid species, the detection limit of minor but important lipid species can thus 
be enhanced [20]. Consequently, more meaningful and unambiguous 
information can then be obtained from the lipidomics analysis. Due to its high 
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selectivity, rapidity and convenience without prior chromatographic 
separation, targeted lipidomics is therefore also a popular choice amongst 
investigators in quantification of lipids [10].  
 
Nevertheless, no technique is perfect and the key drawbacks in direct-infusion 
ESI-MS-based technologies are the effects of strong ion suppression when 
analyzing lipid mixtures [1, 27] and the inability to resolve isobaric 
compounds [10]. Strong ion suppression is often brought about by the 
competition between various analytes in the mixture for charge during the 
process of ionization. Subsequently, when the ion counts of a particular lipid 
is being measured, its observed counts may be much lower depending on the 
analytes or contaminants is it being co-ionized with [14]. To counter this 
problem, suitable internal standards having the same ionization properties as 
the lipid of interest can be spiked into the mixture to quantify them more 
accurately [2, 10]. However, it should be noted that due to the magnitude of 
the number of individual lipid species present in biological samples, 
considerable efforts would be required in this decision, depending on the 
choice and availability of the relevant lipid standards.   
 
Fortunately, both the problem of ion suppression and resolution of isobaric 
lipids can be overcome, to a certain degree, with one or more chromatographic 
technique prior to MS analysis [28]. Typically, a highly efficient 
chromatographic separation, known as high performance liquid 
chromatography (HPLC) is used to resolve complex lipid mixtures prior to 
MS analysis [10].  Depending on the lipid of interest, both normal phase (NP) 
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and reverse phase (RP) chromatography can be used to separate the different 
individual lipid species. In NPLC, lipids are separated based on their class [2], 
while in RPLC, lipids are separated based on their lypophilicity determined by 
their carbon chain length and number of double bonds [29]. Through either of 
the chromatography method prior to MS, ion suppression gets significantly 
reduced as the number of competing anlaytes entering the MS ion source at 
the same time is reduced [10]. Moreover, the use of chromatography enhances 
the quality of the results, as the chromatographic peak of lipid analytes would 
be located at a characteristic retention time with their specific mass-to-charge 
ratio (m/z), allowing isobaric lipids to be resolved in the process [10].  
 
When it comes to analysis of volatile and low molecular mass lipids such as 
fatty acids, one would turn to gas chromatography mass spectrometry 
(GCMS). Since being founded in 1950s [30], this technique has been a key 
research tool in various fields and is also widely used in lipidomics.  Unlike 
ESI-MS/MALDI-MS analysis, which allows direct analysis of the lipid 
mixtures/tissues, additional steps are required prior to GCMS analysis. Firstly, 
due to the complexity of lipid extracts from biological samples, separation 
using HPLC [31], TLC [32] or solid phase extraction [31] is to be performed. 
Following which, chemical derivatization is also necessary to convert the lipid 
analytes into volatile yet thermally stable forms in order to reduce unwanted 
adsorption effect and increase volatility of the polar compounds [2]. The most 
frequently used fatty acid derivatization method is done by hydrolysis of the 
complex lipids followed by methylation, forming fatty acid methyl esters 
(FAMES) [2]. Despite the fact that sample preparation requires time-
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consuming efforts of separation and derivatization before MS analysis, GCMS 
is still a powerful technique that is used by many to investigate the metabolism 
of fatty acids [2, 10].  
 
Due to its good sensitivity, GCMS is also often used in the analysis of less 
polar lipids such as cholesterol and its oxidation products [13, 33]. Similarly, 
this is not devoid of time-consuming chemical modifications that are required 
to make the lipid analyte volatile prior to MS analysis [13, 34]. Nevertheless, 
the real shortcoming is that these processes reduces the rate of recovery and 
causes the formation of artifacts [13, 34]. Fortunately, LCMS has enabled the 
analysis of lipid mixtures without the need for volatility. However, as 
cholesterol and its oxidation products are relatively less polar, ionization of 
these lipids in ESI mode is not as efficient [13]. But with an alternative 
ionization source such as APCI, this problem is overcome, making analysis of 
cholesterol and its oxidized products through the use of LC-APCI-MS very 
successful [13, 33].  
 
Evidently, there is no single step technique that can be used to analyze all 
lipids species in a biological sample. Only through the use of a combination of 
analytical techniques with the utilization of a range of mass spectrometry 
technology would the comprehensive lipidome of various biological samples 




1.2 Blood cell lipidome in biomarker development  
1.2.1 The basis of lipidomics in biomarker development 
Lipids are highly diverse in nature and are versatile dynamic regulators of 
several cellular processes [11]. They are known to be tightly regulated, so as 
to maintain the integrity of carrying out their physiological function. 
Interestingly, even though cells are exposed to a diverse nutritional 
composition of organismal diets, the lipid make-up in cellular membranes 
remains to be remarkably consistent. This highlights a specific homeostatic 
mechanism in ensuring maintenance of the lipid composition [39]. 
 
Indeed, failure in lipid metabolism and regulation would have a deleterious 
effect on the cell or organism, which contributes to disease pathophysiology 
[39, 40]. Consequently, identification of the presence of a signature lipid 
aberration becomes a useful phenotype [39] as deviation from the precise 
balance of lipids and their effectors could serve as biomarkers in providing 
valuable information in the clinical prognosis or diagnosis of a disease. 
Moreover, the information also helps in understanding how lipid abnormalities 
can affect a pathological state, pointing to potential drug targets. It is thus 
unsurprising that various investigators have studied lipid metabolic 
dysregulation in several human diseases. They include cancer [41-43], 
diabetes [44], obesity [45],  atherosclerosis [46] and even neurological 
disorders [47-49].  
 
When it comes to the application of biomarkers to the prognosis or diagnosis 
biomarkers of diseases, biological samples that are least invasive and easy to 
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obtain are preferred. Depending on the disease of interests, plasma [50, 51], 
blood cells [52], urine [53], ascites fluids [43], synovial fluids [54], 
cerebrospinal fluid [48] and also tissues (whenever possible) [41, 55] have all 
been used in biomarker discovery. The choice of samples for lipid based 
biomarker development is plentiful. However, this thesis will only focus on 
lipid biomarkers in blood cells.  
 
1.2.2 Significance of blood cell lipidomics in biomarker development 
Blood is a major component in our body and acts as a fluid organ that 
encompasses every part of us. It performs three major function: (1) It 
transports oxygen and nutrients throughout the body; (2) it regulates bulk 
equilibria; and (3) it is an important part of our immune system [56]. The 
major composition of blood comprises erythrocytes, leukocytes and platelets. 
As it appears, different human blood cells have a unique and cell specific lipid 
composition [57]. The characteristic lipid pattern would match their functional 
requirements according to the blood cells’ shape and size in the vascular 
system [11]. Composition and organization of these blood cell lipids are 
tightly regulated. Therefore, alteration in any form often leads to the loss of 
function and results in early removal from the circulation [11, 58]. More 
importantly, abnormalities in the lipid components of blood cells, if captured, 
can act as useful biomarkers reflecting the biological state; pathological stage 
of the disease or the body’s response to a therapeutic intervention at any given 
point in time [59]. Furthermore, unlike other tissues and organs, blood is 
easily accessible in a clinical setting, making it an ideal site for obtaining 
specimens in the diagnosis and prognosis of a given disease. This is especially 
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useful in diseases with vague symptoms or mental disorders which currently 
do not have any validated laboratory methods for use in the diagnosis and 
routine care of the disease [60]. As a result, it is important to study the lipid 
composition of circulating blood cells in high details. Not only does it help to 
identify the presence of novel blood based lipid biomarker of various diseases, 
it can also act to evaluate any blood cell defects that possibly lead to disease 
progression. 
 
1.2.3 Erythrocyte as a stable biomarker 
Amongst the various types of blood cells, erythrocytes are the most ideal cell 
type for biomarker studies. This is because the erythrocyte lipidome is perhaps 
more stable than the rest since they are highly abundant. As shown in Table 
1.1, the average turnover of the erythrocytes (i.e., 120 days) is considerably 
slower [61, 62], less brief than that of the platelets (i.e., 7-10 days) [63, 64] 
and undoubtedly less variable than the leukocytes (i.e., hours to years). 
Furthermore, these cells are also deemed as stable biomarkers due to their 
uniformity and simplicity. The mature erythrocyte is seen as a “donut sac” that 
does not contain any intracellular membrane compartments other than its 
plasma membrane component [65]. As such, any lipid pattern that may be 





Table 1.1 Characteristics of different blood cells. 




During the 120 days lifespan of the erythrocytes in circulation, these cells are 
non-dividing with a relatively stable cell membrane [66]. In fact, little or no 
turnover of the plasma membrane is present as the mature erythrocyte 
completely loses its ability to produce membrane lipids once it matures [65, 
66]. However, remodeling of the erythrocyte membrane lipids is not 
impossible. Enzymes such as phospholipase, CoAligase and acyltransferase 
that play important metabolic roles have the ability to do so [65, 66]. 
Fortunately, activities of these enzymes are lower in the mature erythrocytes 
[66] and hence result in a relatively slower turnover [67, 68]. It should also be 
noted that other cells in the circulating blood could also release these enzymes, 
acting on the plasma membrane of erythrocytes. Nevertheless, a reliable and 
distinctive lipid pattern of the membrane can always be characterized from the 
erythrocytes. Any deviation from the normal lipid composition of the 











Abundance) 200,000)–)500,000/ul) 5,000,000/ul) 4,500)–)10,000/ul)
Lifespan) 7910)days)) 120)days)) Hours)to)years)
SEM Image 
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1.2.4 Structure and function of lipids in the erythrocyte membrane 
Lipids are extremely crucial in the maintenance of the erythrocyte’s shape and 
fluidity [69]. The dominant lipid component of the erythrocyte plasma 
membrane consists of unesterified cholesterol (30%), phospholipids (60%) 
and small amount of glycolipids (10%) [68]. The majority of phospholipids 
present in the erythrocyte membrane includes phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), sphingomyelin (SM), and phosphatidylserine 
(PS) [68]. It is a well-established phenomenon that the lipid bilayer is 
characteristic of having a trans asymmetry distribution where PS and PE are 
almost entirely located in the inner leaflet, while PC and SM are mainly in the 
outer leaflet [68]. Small amounts of lyso-PC, phosphatidylgylcerol (PG), 
phosphatidylinositol (PI), ceramides (Cer) are also known to be present in the 
erythrocyte membrane [11].  
 
With the exception of lysophospholipids and SM, the phospholipid structure 
has a characteristic feature of having a glycerol backbone, attached to two 
fatty acid chains (Figure 1.2(A)). Distinction between subclasses of 
phospholipids is based on the polar head group attached at the sn-3 position of 
the glycerol backbone [70]. Individual species of a particular subclass is 
further differentiated by the fatty acyl chain length and degree of unsaturation 
of the hydrocarbon moieties located at the sn-1 and sn-2 position of the 
glycerol backbone [70]. Typically, the two fatty acid chains is attached by an 
ester linkage. However, there is also a possibility that one of the fatty acid 
chain is attached to an ether or vinyl-linkage, giving rise to ether lipids [70]. 
Likewise, diversity of lysophospholipids, such as lyso-PCs, follows that of its 
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phospholipid counterparts, except that these lipids are lacking one of the acyl 
chains.  
 
Cer and SM, on the other hand, are categorized as sphingolipids (Figure 
1.2(B)). Sphingolipids are distinct in having a saturated or unsaturated 
sphingoid backbone instead of a glycerol backbone [71]. When the sphingoid 
base is amide linked to a fatty acid chain, Cer is formed. Further combination 
of phosphocholine at the sphingoid headgroup would give rise to SM. Instead 
of a phosphocholine residue, sugar residues can also be added at the head 
group to derive more complex sphingolipids such as glucosylceramide 
(GlcCer) and galactosylceramides (GalCer) [71]. Nonetheless, the majority of 
sphingolipids in the erythrocytes are of the SM species [68]. 
 
Cholesterol, the second major lipid component of the erythrocyte is 
intercalated between the lipid bilayer of the erythrocyte plasma membrane. 
Due to its rigid tetracyclic ringed structure as shown in Figure 1.2 (C), 
cholesterol is known to control the fluidity of the membrane by restricting the 
motion of the fatty acyl chains [72]. Unlike phospholipids, which have a trans 
asymmetry distribution, cholesterols are more equally distributed on both 
sides of the lipid bilayer [68] (Figure 1.1). Through process of oxidation at 
different position of the cholesterol, lipids known as oxysterols can be 
produced and found in small amounts of the erythrocyte membrane [73]. 
 
In general, combination of various lipids of the plasma membrane with 
difference in (a) phospholipid class, (b) degree of fatty acid unsaturation, (c) 
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acyl chain length, (d) cholesterol type (free or esterified) and (e) presence of 
amphipathic lipids are all factors that determine the erythrocyte’s shape and 
fluidity [69, 74]. More importantly, these lipids are not just membrane 
components but are also known to serve important functional roles. Most 
notably, the exposure of PS is involved in the signaling mechanism of 
phagocytosis, cell death and apoptosis [9, 68]. Others such as lysoPC, lysoPA 
and PA are known to be signaling induced messenger lipids [9]. Likewise, SM 
is involved in regulation of endocytosis [75] and receptor-mediated signaling 
[76]. Moreover, SM is also essential as a direct precursor of Cer [77]. The role 
of Cer includes the participation of cell proliferation, apoptosis and cellular 











Figure 1.1 Diagram depicting the lipid bilayer of the erythrocyte membrane. 
The major lipid component of the erythrocyte plasma membrane consists of phospholipids 
(60%), unesterified cholesterol (30%) and glycolipids (10%). This membrane has a 
characteristic bilayer in which the major phospholipids entail the phosphatidylcholine (PC), 
phosphatidylserine (PS), phosphatidylethanolamine (PE) and sphingomyelin (SM). These 
phospholipids are distributed in a trans asymmetry where the entire PS and PE are found to be 
almost entirely on the inner leaflet while PC and SM are mainly on the outer leaflet. In 




































































Figure 1.2 Lipid structure of major erythrocyte membrane lipids. 
(A) Phospholipid structure is characteristic of having a glycerol backbone, attached to two 
fatty acid chains. Distinction between subclasses of phospholipids is based on the polar head 
group attached at the sn-3 position of the glycerol backbone. Further differentiated of the 
subclass is brought about by difference in fatty acyl chain length and degree of unsaturation of 
the hydrocarbon moieties located at the sn-1 and sn-2 position. The majority of fatty acid 
chains are attached to an ester linkage. Fatty acids can also be attached to an ether or vinyl-
linkage to give rise to ether lipids. (B) Sphingolipids have a distinct saturated or unsaturated 
sphingoid backbone. When the sphingoid based is to a fatty acid chain via an amide linkage, a 
ceramide (Cer) is formed. Based on the residue added at the headgroup, other more complex 
sphingolipids are derived. They include sphingomyeline (SM), glucosylceramide (GlcCer) 
and galactosylceramide (GalCer). (C) Cholesterol structure has a distinctive rigid tetracyclic 
ring structure, which is known to control the fluidity of the membrane by restricting the 
motion of the fatty acyl chains.  
 
1.3 Hurdles in erythrocyte lipidome biomarker study  
1.3.1 The missing piece  
The clinical benefits of biomarkers are irrefutable but delivering a set of 
reliable biomarker is no easy task. Measurement of lipid aberrations in hopes 
of discovering useful biomarkers for diseases is routinely done but its success 
may not always be easy. This is contributed mainly by two problems, 1) 
technical and 2) biological variation. In both cases, the presence of high 
variation causes the detection of valuable biomarkers to be masked. Even 
when a signature biomarker is being identified, its reliability is often 
questionable. This is because one needs to be certain that the signature 
biomarker is in fact the metabolic end product of a biological effect and not 
derived from random technical variations of the experimental approach and/or 





which are already present in healthy individuals. Nevertheless, even with good 
experimental techniques and stringent sampling criteria, it is only in theory 
and never in reality that these variations can be completely eliminated. As 
such, an in-depth study to characterize and quantify both technical and 
biological variations in the erythrocyte lipidome is thus required. More 
importantly, this information should be applied to biomarker discovery to 
ensure that a reliable and meaningful signature is being elucidated from the 
study.  
 
1.3.2 Attributions of technical variation 
Having a large sample size is a prerequisite to biomarker discovery as 
biological diversity in the population can easily impact the power and 
confound statistical analysis [81]. As such, conducting large-scale studies 
requiring multiple-batch experimental design is mandatory in biomarker 
development. However, the immediate consequence is an inevitable increase 
in technical variation as compared to traditional small-scale studies [81]. 
 
Technical variation may be attributed to many components and summarized in 
Table 1.2. In general, appropriate conditions for collecting, handling, and 
storing study samples in a standardized way, along with trained personnel are 
necessary to preserve the integrity of the lipid analyte [82]. When done 
improperly, analytical outcomes can become drastically affected. Optimization 
of a standard sample processing protocol is therefore essential to minimize 
such issues. In addition, repeated cycles of freeze thawing the samples are to 
be avoided to prevent them from being compromised. To circumvent this, one 
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should aliquot the samples into smaller volumes prior to storage. Furthermore, 
difference in storage conditions would also introduce variability. To reduce 
this inconsistency, storage tubes of the study samples are to be kept uniformly 
and all stored at -80oC to impede any degradation of the lipid mixtures. 
Integrity of the reagents used in each study is also crucial in minimizing 
variability. As different batches of solvents/reagents are subjected to 
disparities in terms of quality and stability [82], it would thus be ideal to use 
the same batch of solvents/reagents throughout each biomarker study to limit 
variability. Care should also be taken in preparation of the solvents/reagents. 
This includes preparation of fresh mobile-phase solvents and reagents for each 
batch of analysis to avoid varying concentration due to evaporation; 
formulating them by the same individual to avoid any form of human error 
amongst different individuals. Also, ensuring the use of the same, cleaned, 
glassware to lower the possibility of variation from contaminants.  
 
More importantly, special attention needs to be given to the analytical 
instrument to ensure reproducibility and accuracy of the data. Other than 
making sure the source of the analytical instrument is not contaminated and at 
its optimum state, conditioning the column before analysis of the actual 
samples is just as crucial. It is recognized that the first few injections of 
sample usually gives unrepresentative results from small changes in signal 
intensity and/or chromatographic retention time shifts [83].  As such, injection 
of five to ten samples would be required to stabilize the retention time as the 
column becomes “conditioned” for the run. Typically, quality control (QC) 
samples are employed for this purpose. QC samples are identical samples 
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pooled from aliquots of lipid extracts and is representative of biological 
composition of the study samples [84] which are injected at the start of the run 
to condition the column. Interestingly, QC samples are also required in other 
areas. As mentioned earlier, biomarker studies have to be large-scale to ensure 
a robust outcome. However, this would mean that not all samples could be 
analyzed in a single analytical run. Instead, analysis in a multiple batch 
fashion would be required in order to counter long-term reproducibility of the 
instrument and the need for preventative maintenance [85]. Precision and 
reproducibility is highly dependent on the analytical instrument and may 
change in response over time. For this reason, QC samples should therefore be 
injected periodically across the run to document the analytical performance of 
the machine. An evaluation of acceptability within each analytical batch is 
based on the technical precision determined by the percentage (%) coefficient 
of variation (CV) of all the QC samples that were included throughout the run 
[85]. Based on good laboratory practice (GLP) guidelines, an analytical assay 
for lipids is satisfactory when at least 67% of the QCs fall within 15% of its 
nominal value [86]. Furthermore, data of QC samples are also valuable in 
allowing correction of within and between analytical batches to be achieved 








Table 1.2 List of components that may attribute to technical variation. 
Cause Remedy 
(A) Sample Processing (Collecting and Handling) 
1) Drawing Blood Done by the same phlebotomist 
2) Circadian Rhythm Samples drawn at the same of the day (i.e. 8-10am) 
3) Environmental contribution 
All samples to be centrifuged, washed, 
aliquoted, stored at -80oC within 1 
hour from being drawn  
(Standardized protocol) 
(B) Storage 
1) Quality of the tubes Use the same type of tubes for all samples 
2) Multiple freeze-thawing causing 
instability of lipid extracts 
Aliquot samples accordingly before 
storing to avoid freeze-thawing 
3) Differing storage conditions All samples must be stored in the same -80oC freezer 
(C) Solvent/Reagent Integrity 
1) Contamination of glassware 
i.  Rinse well before use 
ii.  Use the same solvent/reagent 
bottles 
2) Purity of reagents/solvents Use HPLC-grade solvents/reagents from the same batch 
3) Varying solvent concentration 
i.  Prepare fresh solvents for each batch 
of samples 
ii.  Use the same measuring cylinder 
ii.  Prepared by the same individual 
iv. Prepared in the same bottle 
(D) Machine Stability 
1) Varying temperature of mobile 
phase solvents 
Use mobile phase solvents only at 
room temperature 
2) Column condition  i.  Condition the column before use ii.  Clean or replace column routinely  
3) Machine condition Clean and change components of the source routinely 
 
1.3.3 Attributions of biological variation (BV) 
Erythrocytes are amongst the most substantially studied cells in the course of 
natural history. Due to their high morphological homogeneity, these cells are 
often thought to have a high degree of uniformity in our biological system 
[87]. However, this may not be the case. The erythrocyte life cycle consists of 
three distinct stages, i.e., the reticulocytes (young), the matured erythrocytes 
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and the aged erythrocytes (Figure 1.3). All three stages coexist in the 
circulation at any point in time. 
 
Figure 1.3 Diagram depicting the assortment of erythrocytes at different stage of their 
lifespan.  
Life cycle of the erythrocyte begins in the bone marrow where, the hematopoietic stem cell 
becomes a burst-forming unit-erythroid (BFU-E), followed by a colony-forming unit-
erythroid (CFU-E). Having receptors for erythropoietin (EPO), the CFU-E gets stimulated and 
transforms into an erythroblast. The erythroblast multiplies and synthesizes hemoglobin, once 
this is completed; the nucleus of the erythroblasts shrivels and is released from the cells. It is 
then called the reticulocyte. The reticulocyte leaves the bone marrow and finds its way into 
the circulating blood. The matured erythrocyte circulates in the blood stream for an average of 
120 days. With increasing time in the circulation, the matured erythrocyte starts to age, 
becoming smaller and denser known as aged erythrocyte. 
 
Briefly, the life cycle of the erythrocyte begins in the bone marrow where, the 
hematopoietic stem cell becomes a burst-forming unit-erythroid (BFU-E), 
followed by a colony-forming unit-erythroid (CFU-E). Having receptors for 
erythropoietin (EPO), the CFU-E gets stimulated and transforms into an 
erythroblast. Initially, the erythroblast multiplies and synthesizes hemoglobin, 
but once this is completed, the nucleus of the erythroblast shrivels and is 
released from the cell. The product is a cell with only ribosome clusters left, 
called the reticulocyte. The reticulocyte leaves the bone marrow and finds its 
way into the circulating blood. In a healthy individual, approximately 0.5 to 
1.5% of the erythrocytes in our circulation are reticulocytes. In a span of a day 
or two, the reticulocyte develops into a matured erythrocyte by losing its last 






stream for an average of 120 days. With increasing time in the circulation, the 
matured erythrocyte starts to age, becoming smaller and denser (aged 
erythrocyte). When this happens, the erythrocytes lose 30% of their volume 
and 15-20% of their hemoglobin [89]. Other than the change in cell volume 
and size, various investigators have also reported other peculiar characteristics 
of aged erythrocytes to be correlated with increase in glycated hemoglobin 
(HbA1c) [90], cell deformability [91, 92] and osmotic fragility [93]. Lipid 
related alterations including PS exposure [94] and decreases in total lipid, 
cholesterol and phospholipid content [95] also occur in aged erythrocytes. 
When it comes to functionality, evidence has shown that the erythrocytes in 
different stage of their lifespan are also heterogeneous [87]. Taken together, 
seemingly similar erythrocytes are really not so identical. To complicate 
matters, variability in the erythrocytes lipidome within- and between- 
individuals may also be present due to multiple factors such as age, gender, 
ethnicity, diet, cyclical rhythms, physical activities and homeostasis [96].  
 
1.3.3.1 Genetic and dietary effects 
To date, the two most investigated sources of biological variation (BV) in the 
erythrocyte lipidome are in areas of genetic and dietary effects. The genetic 
make up of different individuals is heterogeneous. Thus, it may not come as a 
surprise to find this element to be a strong attributor of BV in the erythrocyte 
lipidome. A number of reports have shown that variability in polyunsaturated 
fatty acid (PUFA) composition of serum phospholipids in both the Europeans 
and Han Chinese population is strongly associated with the genetic variants of 
fatty acid desaturase 1 and fatty acid desaturase 2 (FADS1 and FADS2) gene 
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cluster [97-100]. Interestingly, these associations with FADS1 and FADS2 
were also established in the PUFA of the erythrocyte membranes [97, 101]. In 
particular, FADS1 and FADS2 genes were found to influence the proportions 
of long-chain omega-6 PUFA in the erythrocytes such as dihomo-γ-linolenic 
acid (LA) and arachidonic acid (AA) [97, 101]. A significant increased in LA 
and a significant reduction in proportions of AA was observed in the 
erythrocyte membrane [97, 101]. Interestingly, these associations were also 
found in minor alleles of FADS1 SNP (rs174537, rs174550) and FADS2 SNP 
(rs174561) [99, 101]. Taken together, these studies establish and support the 
association of genes having a dominant effect on the pattern of erythrocyte 
lipids.  
 
Moreover, a distinctive diet can also influence and modify lipid metabolism. 
Even in a genetically similar population, one might observe much variability 
due to dietary habits. Based on numerous publications on nutritional studies, it 
is clear that dietary effects can influence the phospholipid composition of the 
erythrocytes. Evidence has shown that during dietary changes, the 
predominant factor in determining the erythrocyte membrane composition is 
based on fatty acid transfer from the plasma to the erythrocyte [102]. This has 
been well supported by short-term dietary studies ranging from 8-16 days, 
where distinctive alteration in erythrocyte phospholipid fatty acid content are 
observed with extreme changes in dietary fat intake [102, 103]. Interestingly, 
the most susceptible diet-induced alteration is seen in the PC (lecithin) fraction 




Likewise, long-term dietary effect on the erythrocyte phospholipids is also 
well documented. An epidemiological study conducted by Dougherty et al. 
[104] demonstrated that normal subjects from different parts of the world (i.e., 
Italy, Finland and the United States of America (USA)) have characteristics 
fatty acid patterns reflected in their erythrocyte membrane. This is due to the 
long-term dietary habits of each location. Through dietary analysis of the 
subjects, it was shown that levels of saturated fatty acids were consistently 
higher in the erythrocyte samples from the Finnish as their diet is loaded with 
large amount of saturated fat attributed by their high intake of dairy products 
and fatty meats [105, 106]. The Italians, on the other hand, have the highest 
levels of mono-unsaturated fatty acids in the erythrocyte membranes from the 
frequent consumption of olive oil in their diet [105, 107]. The Americans, in 
contrast, generally had higher PUFA in their erythrocyte membrane as they 
have a tendency to use more polyunsaturated oil and margarines in their food 
[108].  
 
1.3.4 The missing link in BV 
BV in the erythrocyte lipidome has long been recognized by biologists and is 
accepted to be present due to the diverse interaction of genome and the 
environment [85]. As a result, fasting blood samples are often requested by 
investigators in erythrocyte lipidomics studies as a precaution to avoid any 
chance of dietary influence. However, to date, the requirement of needing 
fasting blood samples to study the erythrocyte lipidome has yet been 
thoroughly investigated. Likewise, selection of participants in erythrocyte 
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lipidomics biomarker studies is often well matched for gender and ethnicity to 
minimize genomic influence. Yet, it is undeniable that even after stratifying 
individuals to be of the same gender and ethnicity, influence from factors of 
age, cyclical rhythms, physical activities and homeostasis [96, 109] still 
persists.   
 
Undeniably, the understanding of BV in the erythrocyte lipidome brought 
about by factors, other than gender and ethnicity is less known. Furthermore, 
variability due to BV is often ignored and assumed to not influence the 
outcome in biomarker development. As a consequence, much work needs to 
be put in by investigators to grasp the science behind it. More importantly, add 
value by developing a framework, which applies knowledge of BV to 
elucidate stronger biomarkers.  
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2. Motivation and Experimental Approaches  
 
As described in the previous chapter, erythrocytes are good candidates in 
biomarker studies due to their innate properties. They can therefore serve as 
valuable markers in the prognosis and diagnosis of diseases. However, the 
success in biomarker development is limited by the lack of investigation on 
variations involved in each study. This is crucial for biomarker development, 
as these studies are all subject to variation [110]. Yet, investigators today 
generally neglect this and are thus unable to truly determine if a signature 
marker is indeed elucidated due to the pathological condition or in fact 
attributed by the inherent contribution of technical and biological variations.  
 
Technical variation can come about through sample processing, storage, 
integrity of chemicals/reagents and precision of the analytical instrument. On 
the other hand, biological variation (BV) in a healthy population arises from a 
combinational effect of age, gender, ethnicity, diet, cyclical rhythms, physical 
activities and homeostasis [96]. As such, understanding and preferably 
quantifying these variations would be highly valuable as they can then be 
applied in biomarker development to better identify pathologically related 
signature markers.  
 
Taken together, the aim of the thesis is to quantify both technical and 
biological variations in the erythrocyte lipidome of a homogenous group of 
individuals. After which, this information is used to help facilitate the 
identification of reliable biomarkers in disease states. To demonstrate this 
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framework, biomarker development of the erythrocyte lipidome in the 
diagnosis of schizophrenia will be examined in this thesis. As a summary 
(Figure 2.1), the following will be performed to fulfill the above aim: 
 
(i) The natural BV in the study of erythrocyte lipidome for each lipid 
species will be characterized by 
a. Elucidating if the need for fasting blood samples is required in 
study of the erythrocyte lipidome. 
b. Quantifying BV of fasting erythrocyte samples across 120 days 
in a healthy homogenous population. 
(ii) A novel lipid based diagnostic biomarker in schizophrenia will be 
elucidated by 
a. Establishing a comprehensive lipid profile of erythrocytes 
between schizophrenic patients and healthy controls. 
b. Providing insights to biomarker development based on 
knowledge of (i). 
c. Explaining any lipid abnormalities found between 
schizophrenic patients and healthy controls.  
 
(iii) Most importantly, technical variation, which exists due to the 
course of sample processing and imprecision of measurement by 
the analytical instruments, will be examined in all studies to 
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3. Materials and Methods 
 
This section on materials and methods is common for all chapters. Additional 
materials and methods that are relevant to each chapter will be provided 
separately. 
 
3.1 Chemicals and reagents 
HPLC grade chloroform and methanol were purchased from Fisher Scientific 
(Loughborough, UK). Ultra-pure grade PBS was purchased from Vivantis 
Technologies (Sdn Bhn, Malaysia) and ultra pure grade Tris Buffer pH 7.4 
was purchased from 1st BASE (1st BASE, Singapore). Deionized water was 
obtained from a MilliQ purification system (Millipore, Bedford, MA, USA). 
All other reagents, including ethylenediaminetetraacetic acid (EDTA), 
piperidine and ammonium hydroxide (28% in H20) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated. 
 
Polar lipid standards, phosphatidic acid (PA-17:0/17:0), dimyristoyl 
phosphatidylcholine (PC-14:0/14:0), dimyristoyl-sn-glycero-3-
phosphoethanolamine (PE 14:0/14:0), dimyristoyl phosphatidyglycerol (PG-
14:0/14:0), dimyristoyl C14-phosphatidylserine (PS-14:0/14:0), 
Nheptadecanoyl-D-erythro-sphingosine (C17-Cer), D-glucosyl-ß1-1'-N-
octanoyl-D-erythro-sphingosine (C8-GlcCer), lauroyl sphingomyelin (C12-
SM) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 2-
 29 
dioctanoyl-glycero-3-phosphoinositol (PI-8:0/8:0) was obtained from Echelon 
Biosciences, Inc. (Salt Lake City, UT, USA).  
 
Neutral lipid standards, cholesterol-d6, C18 cholesterol ester-d6, 7β-hydroxy-
cholesterol-d7, 24S-hydroxy-cholesterol-d7, 7-ketocholesterol-d7, 22R-
hydroxy-cholesterol-d7, 5,6-epoxy-cholesterol-d7, 7-dehydrocholesterol-d7, 
27-hydroxy-cholesterol-d6, lanosterol-d6, 25-hydroxy-cholesterol-d6 were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). 
 
3.2 Membrane preparation and lipid extraction  
The erythrocyte membranes were prepared based on a modified method of 
Hanahan and Ekholm (1974) [111]. In brief, the erythrocytes were lysed in 
20mM Tris (pH 7.4) and centrifuged at 4oC, 16000 g for 1h. The acquired 
membrane pellet was washed twice with 20mM Tris (pH 7.4) to obtain a 
colourless membrane fraction. The fractions were re-suspended with 250 µl of 
20mM Tris (pH 7.4) and processed for lipid extraction. Lipids were extracted 
using the modified Bligh and Dyer’s method [112]. In brief, 900 µl of ice-cold 
chloroform: methanol (1:2, v/v) was added to the re-suspended erythrocyte 
membrane fractions and vortexed vigorously for 1 min. After incubation on 
ice for 10 min, 300µl of ice-cold chloroform was added followed by 30 sec of 
vortex. Subsequently, 250 µl of ice-cold deionized water was added followed 
by 1 min of vigorous vortexing. Centrifugal force was used for phase 
separation and the lower organic phase containing the lipids was transferred to 
a fresh tube. Aqueous phases were re-extracted with 500 µl of ice-cold 
chloroform and the organic fractions were pooled and dried under vacuum 
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(Thermo Savamt SpeedVac with UVS400A Universal Vacuum system). 
Lipids were reconstituted in chloroform: methanol (1:1, v/v) prior to analysis 
by mass spectrometry. The reconstitution volume was dependent on the 
amount of hemoglobin (Hb) in the sample (50 mg of Hb à 300 µl of 
chloroform: methanol (1:1, v/v)). A mixture of lipid standard consisting of 
PA-14:0/14:0, PC-14:0/14:0, PE-14:0/14:0, PG-14:0/14:0, PI-8:0/8:0, 
PS14:0/14:0, C17-Cer, C8-GlcCer, C12-SM, LysoPC14:0, LysoPE14:0 
species for polar lipids and cholesterol-d6, C18 cholesterol ester-d6, 7β-
hydroxy-cholesterol-d7, 24S-hydroxy-cholesterol-d7, 7-ketocholesterol-d7, 
22R-hydroxy-cholesterol-d7, 5,6-epoxy-cholesterol-d7, 7-dehydrocholesterol-
d7, 27-hydroxy-cholesterol-d6, lanosterol-d6, 25-hydroxy-cholesterol-d6 for 
neutral lipids were spiked in prior to mass spectrometry.  
 
3.3 Quality control 
An optimized standard pre-analytical processing protocol was executed by a 
group of trained personnel throughout the study in order to limit technical 
variation. Study samples were both prepared and run in a randomized manner 
with similar proportion of various types of samples to prevent systematic bias. 
Good precision of the analytical platform within the FDA’s guideline of 
acceptable was also ensured before analysis of the study samples. A large 
volume of lipid extract was obtained from a packed erythrocyte sample of a 
healthy volunteer. A mixture of standards, which was also used for the study 
samples, was spiked into this lipid extract, mixed well and equally aliquoted 
and stored in -80oC. Whenever an analysis of LC-MRM analysis was 
performed, this sample would be injected 10 times before the analysis of the 
 31 
actual samples, to condition the column and is referred to as CC samples. The 
same sample, this time indicated as QC samples, would also be injected 
periodically, together with the study samples, throughout each batch of 
analysis to document analytical performance of the machine in that run. The 
analytical imprecision of the instrument or analytical variation (CVA) is 
determined by the percentage coefficient of variation (CV%) of all the QC 
samples that were included in the run based on the formula, CVA = (SD/Mean) 
X 100 %, where SD is the standard deviation derived from jackknife 
resampling. 
 
Additionally, a pooled sample of packed erythrocytes from the same 
individual was aliquoted into multiple equal volumes and stored in -80oC. 
These samples are referred to as R samples. Two to three independent R 
samples were extracted together with the actual study samples in each batch to 
determine pre-analytical (only sample processing) variability within each 
batch. The pre-analytical imprecision or pre-analytical variation (CVP) was 
evaluated by the percentage coefficient of variation (CV%) of the R samples 
ran in the same batch.  
 
3.4 Quantitative analysis of LPC, PC, SM, Cer and GlcCer using 
LC/ESI/MS/MS 
Characterization and quantification of phospholipids LPC, PC, SM, Cer and 
GlcCer species was performed as previously described [113] with slight 
modification, using an Applied Biosystems 4000 Q-Trap mass spectrometer 
(Applied Biosystems, California, USA). Prior to introduction into the mass 
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spectrometer, individual lipid classes were separated on an Agilent 1100 high 
performance liquid chromatography (HPLC) system (Agilent Technologies, 
USA) with a Luna 3-μm silica column (i.d. 150 X 2.0mm, Phenomenex, 
USA). A gradient consisting of mobile phase A  
(chloroform:methanol:ammonium hydroxide, 89.5:10:0.5) and mobile phase B 
(chloroform:methanol:ammonium hydroxide:water, 55:39:0.5:5.5) with a 
constant flow rate of 300 μl/min and an injection volume of 7μl was set up. 
For measurement of Cer and GlcCer species, the gradient started from 5% B 
for 1.6 min, followed by linear ramping to 50% B over 8 min. It was further 
ramped up from 50% B to 90% B over 2.5 min and was maintained for 3 min. 
The gradient was then returned to the initial 5% of B in 2 min and maintained 
for another 2 min before the analysis of the next sample. Mass spectrometry 
was recorded under positive ESI mode. Based on product ion and precursor 
ion analysis of characteristics head groups, multiple reaction monitoring 
(MRM) transition was set up for quantification of various Cer and GlcCer 
species. For measurement of LPC, PC and SM species, the gradient started 
from 5% B for 1.6 min, then linearly ramping to 50% B over 10.5 min and 
was maintained for 5 min. The gradient was then further ramped up linearly to 
90% B over 6 min and maintained for 5 min.  The mobile phase was returned 
to 5% over 3 min and maintained for 6 min before the analysis of the next 
sample. Similarly, ionization of the lipids was performed under positive ESI 
mode and detection of various LPC, PC and SM species were based on 
multiple reaction monitoring (MRM) transition of the target lipid and their 
characteristic head groups.   
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3.5 Quantitative analysis of LPE, PE, PG, PA, PI, PS using 
shotgun/ESI/MS/MS  
Characterization and quantification of phospholipids LPE, PE, PG, PA, and PI 
were performed using an Applied Biosystems 4000 Q-Trap mass spectrometer 
(Applied Biosystems, California, USA). 10 μl of sample spiked with standards 
was introduced into the mass spectrometer by an Agilent 1100 Autosampler 
system (Agilent Technologies, USA) with a flow rate maintained at 250 
μl/min. Chloroform: methanol (1:1, v/v) with 2% of 300 mM piperidine was 
used as the mobile phase. The mass spectrometry was recorded under negative 
ESI mode, based on targeted MRM approach of target lipids and their 
characteristic head group. Relevant instrument parameters were previously 
established [114]. 
 
3.6 Quantitative analysis of sterols derivatives using LC/APCI/MS/MS 
Characterization and quantification of cholesterol, cholesterol ester-d6, 7β-
hydroxy-cholesterol, 24S-hydroxy-cholesterol, 7-ketocholesterol, 22R-
hydroxy-cholesterol, 5,6-epoxy-cholesterol, 7-dehydrocholesterol, 27-
hydroxy-cholesterol, lanosterol, 25-hydroxy-cholesterol were analyzed on 
reverse-phase using an Agilent HPLC 1100 system (Agilent, California, USA) 
coupled to an Applied Biosystems 3200 QTRAP mass spectrometer (Applied 
Biosystems, California, USA) as described previously [115]. Briefly, 
separation of these lipids was carried out on a Zorbax Eclipse XDB-C18 
column (i.d. 46 mm X 150 mm, Agilent, USA) using an isocratic mobile phase 
of chloroform: methanol (1:1, v/v) with a fixed flow rate of 500 μl/min. Mass 
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4. Is Blood Sample Collected After Fasting Required for 
Studying the Erythrocyte Lipidome?  
 
4.1 Introduction & Rationale  
Currently, guidelines for health checks recommend the measurement of 
fasting blood sample (>8 hours from the last meal) to decrease variability and 
achieve consistency in the metabolic state of individuals at the time of sample 
collection [116]. However, some studies are now suggesting that non-fasting 
lipid profiles are only minimally different compared to fasting samples and 
may provide a more reliable representative of our metabolic state [117, 118]. 
Cross-sectional studies have found that levels of total cholesterol, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglycerides (TG) are, at most, slightly altered with respect to normal diet in 
individuals [117] while apolipoprotein levels remain unchanged in response to 
normal food intake [118]. As a result, some investigators now see that there is 
no substantial evidence to demonstrate that fasting lipid levels are more 
representative compared to non-fasting levels but perhaps simply followed as 
a worldwide norm [118].  
 
Likewise, fasting blood is also chosen as a standard starting material for 
lipidomics research to eliminate any possibility of dietary influence on the 
experimental outcome. This is not surprising as there is multitude of evidence 
to show dietary influence within the blood lipidome [104, 119]. This includes 
the erythrocyte lipidome, affected by both short- and long-termed dietary 
effects (ranging from days to years) [102-105, 107]. Nevertheless, these 
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findings were established from extreme dietary changes where individuals 
consumed extreme low/high fat diets for short periods of time, or from 
particular dietary habits of individuals living in a specific location for many 
years.  
 
It has yet to be determined if an individual’s fasting and non-fasting 
erythrocyte lipidomes differ. Hence, this section of the thesis aims to monitor 
a comprehensive group of lipid species representing the erythrocyte lipidome 
from fasting (i.e., 10 hours overnight fast) and non-fasting (i.e., 2 hours after 
standardized breakfast/lunch) blood samples to determine if the erythrocyte 
lipidome from non-fasting blood samples of individuals on normal diets would 
be altered and in turn influence the outcome of biomarker studies. 
 
4.2 Material and methods 
4.2.1 Study design and subjects 
A group of healthy controls (N=7) was recruited in this study. Inclusion 
criteria for the subjects were male, of Chinese ethnicity, aged between 30-39 
with no existing medical conditions. All blood samples were collected in 
accordance to the approval of the ethics community and upon informed 
consent.  
 
4.2.2 Sample collection  
Whole blood from finger-pricks were collected into eppendorf tubes 
containing EDTA for anticoagulation in each subject. Samples were collected 
from each individual at three time points (Figure 4.1). The first time point (T1) 
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was after at least 10 hours of overnight fast, where only the consumption of 
plain water was allowed. The second (T2) and third (T3) time points were 2 
hours after a standardized breakfast and 2 hours after a standardized lunch, 
respectively. The energy and nutritional content of the standardized breakfast 




Figure 4.1 Schematic representation of the various time points where blood samples was 
collected from the 7 healthy volunteers.  
The first time point (T1) was collected after at least 10 hour of overnight fast, second time 
point (T2) was 2 hours after a standardized breakfast and the third time point (T3) was 2 hours 
after a standardized lunch.  
 
4.2.3 Isolation of erythrocytes 
In brief, whole blood was centrifuged at 4oC, 1000g for 10 min to separate the 
erythrocytes from the plasma. After the removal of the plasma, the buffy coat 
was also carefully removed. A volume of packed erythrocytes was drawn from 
well below the surface to avoid any residual of the buffy coat. This 
erythrocyte fraction was subsequently washed thrice. Each wash entailed the 
addition of five times the volume of PBS (pH 7.4), gentle dispersion of 
erythrocytes by inverting the tubes 2-3 times, followed by centrifugation at 
4°C, 1000g for 10 min. The saline wash was then aspirated and discarded. The 
final saline wash was discarded leaving the packed erythrocyte fraction. An 
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while the remaining were divided into aliquots of 100 µl and stored in -80oC 
until lipid extraction. 
 
4.2.4 Hb measurement 
The Hb concentration of the packed erythrocyte in each sample was 
determined using a commercial Hb Colorimetric Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA) in accordance to the 
manufacturer’s protocol. Briefly, 20 µl of a 12X-diluted sample was added in 
the well of a 96-well microtitre plate, together with 180 µl of hemoglobin 
detector and incubated at room temperature for 15 min. After which, its 
absorbance at 570 nm was measured using a SpectraMax 190 microtitre plate 
reader (Molecular Devices LLC, California, USA).  
 
4.2.5 Quality control 
Quality control measures were implemented for the study. In brief, QC 
samples and two to three R samples were periodically injected in each batch of 
run to determine analytical and pre-analytical variation, respectively. The 
details were described in Chapter 3.3. 
 
4.2.6 Quantification of phospho-, sphingo- lipids and sterols using mass 
spectrometry  
Erythrocyte membranes were isolated and their lipids were extracted using the 
modified Bligh and Dyer’s method [112] as described in Chapter 3.2. Analysis 
of the respective classes of lipids was also described in Chapters 3.4, 3.5 and 
3.6. 
 39 
4.2.7 Data processing and statistical analysis 
MRM data were extracted using Analyst Software (version 1.4.2, Applied 
Biosystems) and converted into text format. The data was normalized by their 
respective internal standard. Heatplots were generated using MATLAB 
(version 7.0.4, MathWorks Inc., Natick, MA, USA) or software R 
(http://www.r-project.org). Plots depicting principal component analysis 
(PCA) were generated through an orthogonal linear transformation of the 
dataset using R. Fold-change difference of each sample with respect to the 
average of all samples was calculated. Any sample with strong deviation from 
the mean was identified as outlier. Friedman’s test, a non-parametric 
alternative to a one-way ANOVA, was also performed to evaluate the 
difference between groups. Bonferroni’s correction was also performed to 




4.3.1 Subjects and socio-demographic data 
As shown in Table 4.1, the mean age of the seven healthy participants was 
33.29 years (SD 2.06) with an average body mass index (BMI) of 24.46 (SD 
2.92). The group of volunteers comprised a heavy smoker who smoked more 
than 6 cigarettes per day. 
 
Table 4.1 Demographics of the volunteers who participated in the study. 
Demographics of the 7 volunteers 
N 7 
Age (years) 33.29(2.06) 
BMI 24.46(2.92) 
Ethnicity  Chinese 7(100%) 
Non Smoker/ Smoker 6(85.71%)/1(14.29%) 
Smokers classification  Light smoker (smokes 1-5 
cigarettes/day) 0(0%) 
Heavy smokers (smoke more than 6 
cigarettes/day) 1(100.0%) 
 
4.3.2 Acceptability of analytical run (CVA)  
In order to determine the acceptability of the run, the CVA of each lipid 
species monitored was calculated based on the QCs that were periodically 
injected across the run. As shown in Figure 4.2, the average CVA of the lipids 
was <10% thus well within the FDA guideline of <20% for analytical 
precision acceptability [81]. Nonetheless, some lipid species exhibited a CVA 
of >20% with a wide range of variability as denoted by the standard error. 




























































































































































































Figure 4.2 Analytical precision of all the lipids monitored in the erythrocyte lipidome 
represented as CVA (in percent).  
The average CVA of majority of the lipid species monitored was <10% and well within the 
FDA guideline of <20% for analytical precision acceptability [81]. 
 
4.3.3 Acceptability of pre-analytical imprecision (CVP)  
Following the assessment of analytical precision, the pre-analytical 
imprecision due to sample processing was also examined. This was based on 
the replicate erythrocyte samples (i.e., R samples) that were processed 
together with the actual study samples and ran together in the same batch to 
determine the processing variability. This measured imprecision (CVP) would 
include both processing and analytical components. As shown in the heat plots 
(Figure 4.3), the CVP of majority of the lipids were similar to that of the CVA 
thus suggesting that variation due to sample processing was kept to a 
minimum. In fact, some lipid classes, for instance the SM and PC, had CVP 
that were smaller than the CVA, which once more highlighted that the bulk of 





























































Figure 4.3 Comparison of the pre-analytical and analytical precision of all the lipids 
monitored in the erythrocyte lipidome represented as CVP and CVA, respectively (in 
percent).  
It should be noted that the measure of variation due to pre-analytical precision (CVP) is 
inclusive of the contribution of CVA. As shown in the heat plot, majority of the CVP was 
similar to that of CVA thus suggesting that variability due to sample processing was kept to a 
minimal. Some classes of the lipids such as PC and SM have a CVP lower than that of the 





































4.3.4 Data filtering 
To ensure high quality of the dataset, only lipid species with CVA of <20% 
were retained for further analysis. Outliers identified in the study were also 
removed. The list of lipid species that remained after data filtering and used 
for further analysis is presented in Supplementary Table S1. 
 
4.3.5 No change in erythrocyte lipidome with respect to fasting and non-
fasting blood samples 
To determine if non-fasting blood samples of a standard diet would influence 
the erythrocyte lipidome, PCA plots (Figure 4.4) were drawn to illustrate the 
erythrocyte samples of volunteers collected at T1 (at least 10 hours of 
overnight fast), T2 (2 hours after standardized breakfast) and T3 (2 hours after 
standardized lunch) with respect to (A) LPE, PE, PA, PI, PG, (B) LPC, PC, 
SM, (C) Cer, GlcCer, (D) Sterol and when (E) all lipids were considered. No 
obvious patterns were observed in all the PCA plots to suggest that any of the 
lipids monitored were altered in level between the erythrocyte lipidome of the 
fasting and non-fasting blood samples. Similarly, based on Friedman’s test 
(p<0.05), none of the erythrocyte lipids were found to be significantly 
different between the fasting and non-fasting samples (Supplementary Table 
S3). Taken together, both observations concluded that there was no significant 
difference in the erythrocyte lipidome between fasting and non-fasting blood 


























Figure 4.4 PCA plots which depicts the erythrocyte samples of the 7 healthy volunteers 
collected at different time point.  
PCA plots showing the erythrocyte samples of each individual at various time points (T1 – 
after 10 hours overnight fast, T2 – 2 hours after breakfast, T3 – 2 hours after lunch), with 
respect to (A) LPE, PE, PA, PI, PG (B) LPC, PC, SM (C) Cer, GlcCer (D) Sterol and (E) All. 
No obvious patterns were observed in the PCA plots to suggest that the lipids monitored could 
discriminate between the fasting and non-fasting erythrocyte sample. This was supported by 
Friedmen’s test (p<0.05) (data not shown), where no lipids were found to be significantly 
different between the fasting and non-fasting erythrocyte samples. Thus it is concluded that 
there was no difference in the erythrocyte lipidome between fasting and non-fasting blood 







4.4.1 Aim and rationale 
Recent studies have shown that fasting blood sample is not necessary in 
clinical lipid tests as the measured component is only slightly altered in 
response to normal food intake in individuals [117, 118]. In fact, investigators 
believe that there is no substantial proof to show that fasting lipid levels are 
more reliable compared to non-fasting levels. Rather, the practice is followed 
as a worldwide norm [118].  
 
Nonetheless, it is also undeniable that there is a multitude of data to support 
dietary effects on the blood lipidome [104, 119]. Hence, it is not surprising 
that fasting blood samples are often requested in clinical tests and scientific 
experiments so as to eliminate any possibility of dietary effects on the 
outcome. This includes the erythrocyte lipidome, where investigators have 
demonstrated both short- and long-termed dietary influences on erythrocyte 
lipids [102-104, 107, 118]. However, it should be noted that these findings 
were evaluated based on extreme dietary changes in individuals for short 
period of time or established from individuals who have followed particular 
dietary habits for many years.  
 
To date, there has yet been any study that investigates if non-fasting blood 
from a normal diet will have an influence on the erythrocyte lipidome. As 
such, this section of the thesis serves to compare the lipidome of fasting (i.e., 
10 hours overnight fast) and non-fasting (i.e., 2 hours after standardized 
breakfast/lunch) blood samples of a comprehensive list of erythrocyte lipids to 
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determine if fasting alters the erythrocyte lipidome and in turn influence the 
outcome in biomarker studies. 
 
4.4.2 Assessing pre-analytical and analytical precision of the platform  
Before analyzing the erythrocyte lipidome to determine if there is a biological 
difference between the fasting and non-fasting blood samples, both pre-
analytical and analytical precision of the study was first examined. This is to 
ensure that any biological trend observed in the later part is not in fact 
contributed by “noise” of technical variation, but rather a true biological 
signal.  
 
First, the analytical precision of the dataset was examined based on the CVA of 
the lipids. It was observed that majority of them were <10% and thus well-
within the FDA guideline of <20% for analytical precision acceptability [81]. 
However, some lipid species displayed high CVA and they included SM(872), 
PC(927), LPEs, LPCs, DHCers and some sterol derivatives. This is not 
surprising as these lipids either do not exist in the erythrocytes or exist in 
extremely low amounts and are thus undetected by the instrument. The 
phenomenon of lipids with lower concentration having a higher CVA has long 
been reported [120]. This can be explained by the lower limit of detection 
(LOD) in the instrument where background noise due to mobile phase 
components or contaminants influences the detection threshold [121]. For the 
major components of the erythrocyte lipidome such as PCs, PEs, SMs, and 
cholesterol [66], the background noise is negligible as the signal to noise ratio 
(S/N) is so much higher and therefore easily detectable by the instrument. 
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However, for lipids of lesser abundance, the S/N tends to be low [121]. As a 
result, the signal of these low abundant lipids fluctuates, making it difficult for 
the analytical instrument to establish a strong signal from the background 
noise. Nevertheless, to ensure high quality of the dataset, only lipids with good 
precision, based on their CVA of <20%, is used for further analysis as they can 
be reliably measured by the instrument.  
 
Following which, CVP of the study was also assessed. CVP provides an 
indication if samples prepared in the study were done with good laboratory 
practice in order to keep sample processing variability to a minimum. It should 
be noted that the CVP measured in the study takes into consideration the 
instrumental analytical imprecision (CVA). For majority of the erythrocyte 
lipids measured, the CVP was similar to that of the CVA. Interestingly, SM and 
PC had a CVP lower than that of the CVA. This suggests that good laboratory 
practice was indeed implemented since technical variation contributed by 
sample processing was low. Furthermore, the observation also implied that the 
bulk of the variability was in fact derived from imprecision of the analytical 
instrument (CVA). 
 
4.4.3 Fasting and non-fasting blood samples were no different in the 
erythrocyte lipidome 
To my knowledge, this is the first study that specifically examines the 
erythrocyte lipidome from fasting and non-fasting blood samples. Similar 
works have been performed on whole blood samples and looked at usual 
clinical measures such as HDL, LDL, TG, total cholesterol and apolipoprotein 
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[117, 118]. Nevertheless, the finding in the current study is similar to previous 
studies; non-fasting blood of a normal diet has no significant influence in the 
erythrocyte lipidome. The finding hence supports that fasting blood samples 
are largely unnecessary for any clinical tests or scientific experiments that 
examine the erythrocyte lipidome. 
 
4.4.4 Benefits of not needing fasting blood for studies in the erythrocyte 
lipidome 
There are great benefits to not having to provide fasting blood in either clinical 
tests or experimental studies that involves the erythrocyte lipidome. Firstly, 
the finding provides confidence that any signature biomarker elucidated from 
the erythrocyte lipidome is not influenced due to normal dietary effects. This 
is highly valuable as it will allow the erythrocyte lipid biomarker to be used 
whenever required and not only after an overnight fast. Likewise, this will 
increase the compliance of patients who require testing to use the lipid 
diagnostic/prognostic biomarker since the test is convenient and is not affected 
by dietary habits. With respect to experimental studies, not requiring fasting 
blood will also encourage the recruitment of more volunteers. As there is no 
need for volunteers to fast overnight, the period of samples collection is no 
longer restricted to the morning and can be extended.  
 
4.5 Conclusion 
The outcome of this chapter supports that it is not necessary for fasting blood 
samples to be used in the study of erythrocyte lipidome as there is no 
difference in lipid profiles of fasting and non-fasting blood samples. This 
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finding is of great significance to investigators who are interested in the 
elucidation of biomarker in the erythrocyte lipidome as recruitment of 
volunteers may potentially increase since fasting is no longer required. Not 
only will the volunteers be less discouraged to give blood, samples can now 
also be collected throughout the day, allowing flexibility to the volunteers and 
phlebotomists. Moreover, this finding supports the use of the elucidated 
erythrocyte lipid biomarkers at any time of the day, without the need for 
fasting, as the measured outcome is not subjected to change by normal dietary 
effect. 
  
It is clear that the result of this study delivers many benefits involving the 
study of the erythrocyte lipidome. Nevertheless, this study is limited by the 
sample size (N = 7, with 3 time points) and homogeneity of the volunteers 
(males of Chinese ethnicity, age between 30-39). As a consequence, future 
studies including a larger cohort consisting of females and other individuals of 
different age groups and ethnicity will be required to further validate if the 








5. The Index of Individuality in the Erythrocyte Lipidome 
 
5.1 Introduction and Rationale  
Based on comparative studies typically performed between biological 
fluids/tissues taken from diseased and healthy populations, thousands of MS-
based biomarker papers have already been published and yet only a handful 
have made it to clinical practice [122]. With increasing popularity in 
biomarker discovery, good efforts have already been made to address key 
points to limit challenges and pitfalls [123-125]. A major hurdle in biomarker 
discovery is to ensure that the elucidated signature is indeed a metabolic end 
point and not attributed by analytical or biological variation. 
 
Much emphasis has been given to ensure uniformity in sample processing 
(i.e., collection, handling and storage) and precision of the analytical platform 
to allow high reproducibility. Together with experimental execution by trained 
personnel and the use of robust analytical technologies, separation and 
measurement of hundreds of metabolites with high specificity and sensitivity 
have already been made possible [126]. However, less is done in the area of 
biological variation (BV). 
 
The appreciation of BV dated far back since the days of Darwin, where 
biologists have generally recognized that variability in organisms is a sine qua 
non of evolution [127]. However, it was only in 1959 that R. J., Williams 
[127] highlighted the underlying importance of this in the area of biological 
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sciences and medicine. Complexity and diversity in humans are irrefutable 
[128]. Hence, it is well accepted that BV from different individuals arises due 
to the diverse interaction of the genome and the environment [85] and can 
dramatically affect biomarker outcomes [123]. Thus, selection of patients and 
controls recruited in biomarker studies is often well matched for age, gender 
and ethnicity.  
 
However, life is not static. Even in a single healthy individual, the biological 
fluid in his system is continuously fluctuating [129] from the influence of age, 
gender, ethnicity, diet, cyclical rhythms, physical activities and homeostasis 
[96, 109]. As clearly illustrated in Figure 5.1 [126], depending on the factor 
that influences the biological sample and the time the sample was taken from 










Figure 5.1 A diagram with hypothetical changes of measured value of different 
metabolites in healthy and diseased individuals, with respect to time and factor of 
influence.  
(a) Depending on the factor of influence (i.e. aging, infection, circadian rhythm, onset of 
disease), the metabolite measured at a particular instance may be up- or down regulated. (b) 
Bar charts represent the hypothetical ratio of the metabolite of healthy individual to that of the 
diseased as a function of time. Random fluctuation around the homeostatic set point in an 
individual is termed within-subject variation (CVI). Assuming the various metabolites are now 
different individuals, the homeostatic set point varying between different individuals is known 
as between-subjects variation (CVG). Diagram modified from Hawkridge and Muddiman, 
2009 [126].  
 
The concept of BV is not new and was proposed by Cotlove et al. back in 
1970 [130-132]. However, it was only in 1989 where Fraser and Harris [133] 
thoroughly investigated BV for various analytes measured in clinical 
laboratories. Since then, the emphasis of assessing BV has become 
indispensible in clinical laboratory tests and used in everyday laboratory 
practice. Due to the constancy of BV information, there is no need for each 
laboratory to generate its own data of BV [134]. In fact, laboratories can use 
existing BV information published by others. As a consequence, groups from 

















































idea of compiling BV information in databases. Currently, the most up-to-date 
and extensive compilation of frequently measured analytes is available online 
via (https://www.westgard.com/biodatabase1.htm). A wide variety of terms 
have been used in the description of BV. However, to achieve consistency, the 
terms suggested by Fraser and Harris (1989) will be used here, where the 
homeostatic set point varying between different individuals is termed as 
between-subjects variation (CVG) while the random fluctuation around the 
homeostatic set point in an individual is known as within-subject variation 
(CVI) [133-135]. 
 
In the context of metabolomics studies, the innate between- and within-
subjects BV has also been well recognized [136]. Yet, the degree of BV in 
most metabolites (including lipids) is not well studied. Thus, this is an area 
that requires much attention as it has strong implications in biomarker 
discovery. As such, this chapter serves to establish the BV of the erythrocyte 
lipidome in a homogenous population across 120 days. This time frame was 
chosen since the average lifespan of the erythrocyte is 120 days. Furthermore, 
by taking into account the estimates of BV, this chapter seeks to determine if 
the conventional utility of a population-based study is indeed suitable for 
biomarker discovery in the erythrocyte lipidome. In addition, it will provide 






5.2 Material and methods 
5.2.1 Subjects 
A group of healthy controls (N=17) was recruited in this study. Inclusion 
criteria for the subjects were male, of Chinese ethnicity, aged between 30-39 
with no existing predisposed conditions. All blood samples were collected in 
accordance to the approval of the ethics community and upon informed 
consent. 
 
5.2.2 Sample collection and isolation of erythrocytes 
Whole blood from finger-pricks was collected into Eppendorf tubes containing 
EDTA for anticoagulation in each subject. Fasting blood (of at least >10 
hours) were collected from the same subject every 30 days for a period of 120 
days (Figure 5.2). To avoid any metabolic effects due to circadian rhythm, all 
blood samples were collected between 8-10am. Following which, packed 
erythrocytes were isolated from the whole blood as mentioned in Chapter 
4.2.3. 
 
Figure 5.2 Schematic representation of samples collected at various time points.  
Blood samples were collected from 17 healthy male, Chinese, aged between 30-39 every 30 
days for a period of 120 days (5 time points in total). The sample was taken between 8-10am, 









(At least 10 hours) 
Only allowed plain water 
Blood taken between 8-10am 
30 days  60 days  90 days  120 days  
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5.2.3 Hb measurement 
The Hb concentration of the packed erythrocyte in each sample was 
determined as of Chapter 4.2.4. 
 
5.2.4 Quality control 
Quality control measures were implemented for each batch of samples. In 
brief, QC samples and two to three R samples were periodically injected 
during each run to determine analytical and pre-analytical variation, 
respectively. The details were described in Chapter 3.3. 
 
5.2.5 Quantification of phospho-, sphingo- lipids and sterols using mass 
spectrometry  
Erythrocytes were isolated and their lipids were extracted using the modified 
Bligh and Dyer’s method [112] as described in Chapter 3.2. Analysis of the 
respective classes of lipids was also described in Chapters 3.4, 3.5 and 3.6.  
 
5.2.6 Data processing and statistical analysis 
MRM data were extracted using Analyst Software (version 1.4.2, Applied 
Biosystems) and converted into text format. The data was normalized to their 
respective internal standard. Heatplots were generated using MATLAB 
(version 7.0.4, MathWorks Inc., Natick, MA, USA) or software R 
(http://www.r-project.org). PCA plots were generated through software R.  
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5.2.6.1 LOESS (locally estimated scatterplot smoothing) normalization 
A robust QC-based correction known as LOESS was employed to integrate 
each run. Through this process, drift in lipid signal was corrected for in each 
subject in relation to the observed change in the QC samples.  
 
5.2.6.2 Deriving variances 
Data were checked for normality and outlier values using the Shapiro-Wilk 
test and Cochran test, respectively. Estimates of the underlying between-
subject variance, VG and within-subject variance, VW (between-day and 
inclusive of biological and analytical variation) were determined based on 
analysis of variance with subject as random effect. Subsequently, CVs of 
between subject (CVG) and within subject (CVw) were calculated as the square 
root of the estimated variance divided by the overall mean. CVw was further 
partitioned to CVI to exclude CVA using the formula: CVI = (CVW2 – CVA2)1/2. 
Two linear mixed models were fitted where model 2 included day 
(continuous) variable and model 1 one did not. This was done to test for linear 
trend from day 0 (baseline) to day 120. An ANOVA test was applied on the 
two models where lipids with p-value <0.05 would indicate a significant linear 
trend across the 5 time points. Holm-Bonferroni correction was also 
performed to eliminate false discovery.  
 
5.2.6.3 The index of individuality (II) 
The index of individuality (II) [133] of each lipid species was determined by 
the ratio of CVW / CVG (Note: CVw is used as this variance includes CVA). II 
provides an indication of the extent of usefulness a single measurement in 
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assessing the outcome of an individual when compared to a population-based 
reference interval. Fraser and Harris [133] have suggested that the population 
reference interval is maximally sensitive when II is >1.4 and is unsuitable for 
use when II < 0.6. In addition, when II ranges between 0.6 to 1.4, population 
reference interval should be used with caution [137]. The number of required 
repeated measurements (on different days) were also estimated such that the 
homeostatic set point of an individual is within ±	 15% with 95% confidence 










Figure 5.3 The index of individuality (II). 
The II is calculated as the ratio between the within-subject variation (CVW) and between-
subjects variation (CVG), Paradoxically, lipids with index of > 1.4 has low individuality and 
index of < 0.6 is of high individuality. The II is an indicator of the degree of appropriateness 
in the use of a population-based reference interval. Fraser and Harris [133] have suggested 
that the maximum sensitivity for this purpose is when II is >1.4 , where population reference 
interval is suitable and < 0.6, where population reference interval is not useful. However, 
when II is between 0.6 to 1.4, this is a grey area, where population reference interval should 
be used with caution [137].  
 
5.3 Results  
5.3.1 Subjects and socio-demographic data  
Although it has been shown in Chapter 4 that there is no significant difference 
between the lipidome of fasting and non-fasting erythrocytes. Fasting blood 
















of this finding. As shown in Table 5.1, the mean age of the 17 healthy 
participants was 33.82 years (SD 2.32) with an average body mass index 
(BMI) of 24.70 (SD 4.26). The group of volunteers includes a heavy smoker 
who smokes more than 6 cigarettes daily. 
 
 Table 5.1 Demographics of the volunteers who participated in the study. 
Demographics of the 17 volunteers 
N 17 
Age (years) 33.82(2.32) 
BMI 24.70(4.26) 
Ethnicity  Chinese 17(100%) 
Non Smoker/ Smoker 16(94.12%)/1(5.88%) 
Smokers classification  Light smoker (smokes 1-5 
cigarettes/day) 0(0%) 




5.3.2 Determination of the acceptability of analytical run (CVA)  
The acceptability of the analytical run was first determined. Based on the QC 
samples that were periodically injected across the run, the CVA of each lipid 
species within each individual batch and also across the two batches were 
calculated. The CVA of the lipids monitored within each batch ranged from 4 - 
70% (Supplementary Figure S1, CVA of Batch 1 and 2). However, the average 
of the CVA of majority of the lipid species in each batch was <10% and well 
within the FDA guidelines for acceptability of analytical precision [81]. 
 
Similarly, the overall CVA across the two batches, which indicates the 
precision of the analytical platform throughout the study, was also determined. 
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The average of CVA of majority of the lipids between the two batches was 
<15% (Supplementary Figure S1, overall CVA) and was also within the limit 
of satisfaction for analytical precision [81].  
 
5.3.3 Assessing of the pre-analytical precision (CVP)  
The pre-analytical precision was assessed based on the replicate erythrocyte 
samples (i.e., R samples) that were processed together with the study samples. 
The CVP of majority of the lipid species was similar to that of the CVA 
(Supplementary Figure S2). Since CVP is inclusive of CVA, one could infer 
that variability due to sample processing was minimal and that majority of the 
technical variation was contributed by the imprecision of the analytical 
instrument. As a consequence the measure of technical variation in the study 
assumes CVP to be negligible and solely considers the imprecision of the 
instrument measured by CVA. 
 
5.3.4 Data filtering 
To ensure high quality of the dataset, only lipid species with between-batch 
CVA of <20% were retained for further analysis (Supplementary Figure S3) as 
they were comparable with reported values using LC-MS (9-18%) [138] and 
shotgun-MS (10%) [139]. Outliers identified in the study were also removed. 
The list of lipid species that remained after data filtering and used for further 





5.3.5 LOESS correction (Batch effect correction) 
Based on the PCA score plots (Figure 5.4), it was shown that batch-to-batch 
variation was present in the dataset. This was also highlighted in 
Supplementary Figure S1, as the CVA of each individual lipid species between 
the two batches was higher when compared to the within batch CVA of each 
individual batch. Nonetheless, batch-to-batch variation was successfully 
removed by LOESS correction as shown in Figure 5.4, where A-D were the 
before correction PCA plots and E-H were the after correction plots. LOESS 
correction adjusted the drift in lipid signal for each sample with respect to the 
















































































Figure 5.4 PCA score plots of the two batches for dataset of various lipid classes 
measured in the study.  
(A-D) are the uncorrected PCA plots while (E-F) show the LOESS corrected plots. Evidently, 
LOESS correction removed the batch-to-batch variation of the datasets. ‘True’ refers to the 




















































































5.3.6 Between-time variation 
A linear mixed model was used to identify any trends that maybe present 
across 120 days. However, no obvious pattern was found to support any 
significant difference in the erythrocyte lipidome across 120 days (ANOVA 
p>0.05, data not shown). This concluded that the erythrocyte lipidome across 
the 120 days might not be very different due to the effect of time. 
 
5.3.7 Between-subjects and within-subject variation 
The analytical, between- and within-subject variation were calculated and 
reported in Table 5.2. The analytical variation was low, whereas the median of 
the lipids had a CVA of 8.8%. In general, most of the lipids had between-
subjection variation (CVG) higher than that of the within-subjection variation 
(CVI). 
 
5.3.8 Index of individuality (II) 
As described in the methodology of this chapter, II was calculated from the 
ratio of CVW and CVG. In general, the CVW and CVG in the erythrocyte 
lipidome exceeded that of the CVA (Table 5.2). II provides an indicator for 
determining the extent of usefulness in assessing a single measurement of an 
individual’s outcome when compared to a population-based reference interval. 
The suggestion is such that a population reference interval is maximally 
sensitive when II is >1.4 and is unsuitable for use when II < 0.6 [133].  
 
Based on Figure 5.8 and Table 5.2, the II of most lipids in the erythrocyte 
lipidome had low individuality with a median index of 1. This would suggest 
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that the majority of them are in the range where population-based reference 
index would be more suitable. However, it was observed that some of the 
sterol species had an exceptional high II. This observation was most likely 
contributed by the higher analytical imprecision when measuring these lipid 
species (CVA of these lipids are denoted to have values closer to 20%). As a 
consequence, a bias in the CVW was present since this value became much 
higher than it should be due to the contribution of a higher analytical 
imprecision.  
 
5.3.9 Number of samples (on different days) required in estimating the 
underlying homeostatic set point  
In usual clinical or laboratory practice, only a single sample is taken from an 
individual. However, this may not be sufficient as intrinsic analytical and 
within-subject BV influence each result. Such a scenario was observed in the 
erythrocyte lipidome where lipids with extremely high within-subject 
variation would need more measurement to better estimate the homeostatic set 
point in an individual. As shown in Table 5.2, it was evident that a single 
measure in an individual on a single day is insufficient to properly estimate the 
true mean of any of the erythrocyte lipids in an individual. In fact, at least 4 
times of repeated measure would be required for estimation of the homeostatic 





Table 5.2 Tabulation of the analytical and biological variations of the erythrocyte 
lipidome. 
Lipid Species CVG (%) CVI (%) CVW (%) CVA (%) II Na 
LPE(437) 12.2 31.2 32.4 8.5 2.7 17.9 
LPE(453) 21.1 18.0 20.8 10.4 1.0 7.4 
LPE(463) 20.8 27.7 31.2 14.3 1.5 16.6 
LPE(465) 15.2 18.4 19.9 7.4 1.3 6.7 
LPE(477) 25.8 33.5 38.3 18.4 1.5 25.0 
LPE(479) 31.8 19.6 23.1 12.2 0.7 9.1 
LPE(481) 20.4 18.4 20.9 10.0 1.0 7.5 
PE(701) 13.5 12.7 14.6 7.3 1.1 3.7 
PE(715) 16.1 14.8 16.8 7.9 1.0 4.8 
PE(717) 5.8 12.9 14.5 6.8 2.5 3.6 
PE(723) 10.9 13.7 14.8 5.7 1.4 3.8 
PE(725) 9.5 12.3 15.6 9.6 1.7 4.2 
PE(727) 14.0 14.2 16.5 8.3 1.2 4.6 
PE(729) 14.2 14.9 16.1 6.0 1.1 4.4 
PE(739) 6.1 11.8 13.3 6.2 2.2 3.0 
PE(741) 9.6 13.0 14.9 7.2 1.5 3.8 
PE(743) 5.8 13.0 14.8 7.0 2.5 3.7 
PE(745) 7.0 11.3 13.8 7.8 2.0 3.2 
PE(747) 20.2 16.3 17.4 6.2 0.9 5.2 
PE(749) 14.0 14.0 15.9 7.5 1.1 4.3 
PE(751) 5.4 12.6 14.0 6.0 2.6 3.3 
PE(753) 5.7 14.0 15.3 6.0 2.7 4.0 
PE(763) 14.0 12.6 14.8 7.9 1.1 3.8 
PE(765) 2.0 11.7 13.8 7.2 6.9 3.2 
PE(767) 7.6 12.6 14.1 6.2 1.8 3.4 
PE(773) 22.5 15.5 17.0 6.9 0.8 4.9 
PE(775) 15.3 12.3 14.2 7.0 0.9 3.4 
PE(777) 6.4 12.1 13.9 6.8 2.2 3.3 
PE(779) 13.0 14.6 15.8 6.0 1.2 4.3 
PE(789) 17.6 13.8 15.5 7.1 0.9 4.1 
PE(791) 11.8 15.6 16.5 5.2 1.4 4.6 
PA(648) 12.3 10.2 11.2 4.7 0.9 2.2 
PA(672) 10.9 9.5 10.6 4.8 1.0 1.9 
PA(674) 12.2 10.3 11.2 4.4 0.9 2.1 
PA(696) 14.9 7.4 10.3 7.2 0.7 1.8 
PA(698) 10.4 9.6 11.0 5.3 1.1 2.1 
PA(700) 7.6 8.1 10.7 7.0 1.4 2.0 
PA(724) 8.9 10.2 11.8 5.8 1.3 2.4 
PI(834) 25.1 13.9 15.8 7.6 0.6 4.3 
PI(836) 27.4 15.9 17.2 6.7 0.6 5.1 
PI(838) 22.1 8.3 15.6 13.1 0.7 4.1 
PI(858) 24.1 16.3 17.5 6.3 0.7 5.2 
PI(860) 23.3 13.9 16.9 9.7 0.7 4.9 
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PI(862) 20.0 15.4 16.8 6.7 0.8 4.8 
PI(864) 23.0 14.7 16.6 7.7 0.7 4.7 
PI(884) 21.6 16.4 17.8 7.0 0.8 5.4 
PI(886) 20.0 15.3 16.8 6.9 0.8 4.8 
PI(888) 26.6 15.2 16.9 7.4 0.6 4.9 
PI(910) 23.9 14.0 17.4 10.3 0.7 5.1 
PI(912) 22.5 15.0 18.4 10.7 0.8 5.8 
PI(914) 20.3 17.8 20.7 10.5 1.0 7.3 
PS(761) 13.2 10.0 15.4 11.7 1.2 4.0 
PS(763) 14.9 11.4 14.8 9.3 1.0 3.7 
PS(783) 12.0 12.4 16.0 10.2 1.3 4.4 
PS(785) 39.1 19.8 22.5 10.6 0.6 8.6 
PS(787) 48.2 19.2 21.6 10.0 0.4 8.0 
PS(789) 9.2 11.4 15.1 10.0 1.6 3.9 
PS(807) 22.6 17.9 21.3 11.5 0.9 7.7 
PS(809) 12.8 11.0 15.1 10.3 1.2 3.9 
PS(811) 7.1 11.4 15.0 9.8 2.1 3.9 
PS(813) 10.3 11.4 15.4 10.3 1.5 4.0 
PS(815) 14.0 13.2 16.2 9.3 1.2 4.5 
PS(833) 14.7 12.0 15.6 9.9 1.1 4.2 
PS(835) 13.8 12.2 15.2 9.1 1.1 3.9 
PS(837) 0.8 11.2 14.5 9.2 18.4 3.6 
PS(839) 10.6 10.9 14.1 8.9 1.3 3.4 
PS(841) 12.6 12.5 15.9 9.9 1.3 4.3 
PG(720) 15.1 NA 10.9 12.8 0.7 2.0 
PG(722) 11.7 NA 10.2 12.2 0.9 1.8 
PG(746) 9.2 NA 9.7 12.1 1.1 1.6 
PG(748) 14.5 NA 10.1 10.6 0.7 1.7 
PG(750) 8.1 5.0 10.6 9.4 1.3 1.9 
PG(774) 7.8 NA 11.8 13.4 1.5 2.4 
PG(776) 13.0 7.3 13.2 11.0 1.0 3.0 
LPC(507) 8.0 10.2 19.2 16.3 2.4 6.3 
PC(705) 20.8 19.3 20.2 6.0 1.0 7.0 
PC(717) 23.3 8.0 13.2 10.5 0.6 3.0 
PC(719) 19.9 10.1 14.0 9.8 0.7 3.4 
PC(729) 14.0 17.8 20.0 9.1 1.4 6.8 
PC(731) 26.8 13.8 16.5 9.0 0.6 4.6 
PC(733) 7.0 11.6 14.0 7.8 2.0 3.3 
PC(737) 13.9 10.3 15.6 11.7 1.1 4.1 
PC(741) 21.8 3.7 15.4 15.0 0.7 4.1 
PC(743) 17.4 NA 13.0 14.1 0.7 2.9 
PC(745) 13.3 NA 12.7 13.2 1.0 2.8 
PC(747) 12.5 NA 12.0 12.4 1.0 2.5 
PC(749) 22.1 7.0 12.7 10.7 0.6 2.8 
PC(753) 22.4 12.0 17.3 12.4 0.8 5.1 
PC(755) 11.6 13.2 18.2 12.5 1.6 5.6 
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PC(757) 8.0 3.9 12.3 11.7 1.6 2.6 
PC(759) 8.7 NA 11.8 13.1 1.4 2.4 
PC(761) 9.1 2.1 11.4 11.2 1.2 2.2 
PC(765) 27.6 6.2 14.1 12.6 0.5 3.4 
PC(767) 16.0 10.2 14.4 10.2 0.9 3.5 
PC(769) 13.7 5.6 13.7 12.5 1.0 3.2 
PC(771) 14.6 NA 13.4 13.8 0.9 3.1 
PC(773) 13.3 NA 13.0 14.8 1.0 2.9 
PC(777) 24.8 3.2 15.0 14.7 0.6 3.8 
PC(779) 53.1 58.7 59.0 6.5 1.1 59.5 
PC(781) 10.9 9.3 12.1 7.8 1.1 2.5 
PC(783) 10.1 5.8 11.4 9.9 1.1 2.2 
PC(785) 8.6 3.3 11.7 11.2 1.4 2.3 
PC(787) 15.5 7.2 13.0 10.8 0.8 2.9 
PC(789) 16.6 7.6 12.3 9.6 0.7 2.6 
PC(791) 28.6 14.0 16.0 7.8 0.6 4.4 
PC(793) 15.4 12.3 14.2 7.0 0.9 3.4 
PC(795) 12.9 12.1 13.9 6.8 1.1 3.3 
PC(797) 12.6 10.6 13.3 8.1 1.1 3.0 
PC(799) 12.5 10.0 13.9 9.6 1.1 3.3 
PC(801) 15.0 NA 14.5 15.1 1.0 3.6 
PC(803) 15.3 7.7 13.7 11.3 0.9 3.2 
PC(805) 20.9 14.2 15.8 6.9 0.8 4.3 
PC(807) 17.9 14.1 16.0 7.5 0.9 4.4 
PC(809) 12.3 9.4 12.5 8.3 1.0 2.7 
PC(811) 14.9 9.8 11.9 6.7 0.8 2.4 
PC(813) 8.9 NA 13.6 17.7 1.5 3.2 
PC(817) 22.6 19.2 20.8 8.0 0.9 7.4 
PC(819) 19.5 17.2 18.8 7.5 1.0 6.0 
PC(821) 14.6 13.7 15.5 7.4 1.1 4.1 
PC(823) 11.6 13.5 14.3 4.9 1.2 3.5 
PC(825) 10.8 13.1 15.0 7.2 1.4 3.8 
PC(827) 19.1 10.4 15.3 11.3 0.8 4.0 
PC(829) 16.3 9.5 14.4 10.8 0.9 3.6 
PC(831) 18.0 13.8 15.9 7.8 0.9 4.3 
PC(833) 23.0 16.2 17.6 6.8 0.8 5.3 
PC(835) 16.0 12.8 14.6 7.1 0.9 3.6 
PC(837) 13.8 11.9 13.7 6.7 1.0 3.2 
PC(861) 18.3 15.5 19.2 11.3 1.0 6.3 
SM(674) 21.0 8.2 9.6 4.9 0.5 1.6 
SM(688) 27.9 10.4 11.7 5.3 0.4 2.3 
SM(690) 28.7 11.4 12.6 5.2 0.4 2.7 
SM(700) 11.3 8.9 10.8 6.0 1.0 2.0 
SM(702) 7.9 7.8 10.6 7.1 1.3 1.9 
SM(704) 9.0 9.9 12.0 6.8 1.3 2.5 
SM(726) 13.2 12.3 15.6 9.7 1.2 4.2 
 68 
SM(728) 8.4 11.6 13.4 6.7 1.6 3.0 
SM(730) 8.5 11.2 12.1 4.7 1.4 2.5 
SM(732) 14.1 12.4 13.5 5.4 1.0 3.1 
SM(756) 10.4 11.0 13.2 7.2 1.3 3.0 
SM(758) 10.5 10.7 13.8 8.7 1.3 3.2 
SM(784) 11.9 12.8 15.3 8.5 1.3 4.0 
SM(786) 5.8 10.7 13.9 8.9 2.4 3.3 
SM(788) 5.6 5.7 18.2 17.3 3.2 5.7 
SM(798) 22.8 13.3 15.3 7.4 0.7 4.0 
SM(801) 17.2 12.9 14.9 7.5 0.9 3.8 
SM(812) 4.3 12.3 14.7 8.1 3.4 3.7 
SM(814) 3.3 10.6 14.0 9.1 4.2 3.3 
SM(816) NA 8.8 15.0 12.2 NA 3.8 
SM(826) 23.3 11.9 15.1 9.3 0.6 3.9 
SM(828) 12.6 10.8 14.6 9.9 1.2 3.6 
SM(830) 7.5 NA 13.4 13.9 1.8 3.1 
SM(838) 17.6 14.3 16.5 8.2 0.9 4.6 
SM(840) 15.3 13.5 16.0 8.4 1.0 4.3 
SM(842) 10.0 14.9 17.0 8.2 1.7 4.9 
MonoHexCer(755) 18.8 14.2 18.3 11.6 1.0 5.7 
MonoHexCer(783) 21.4 14.3 17.5 10.0 0.8 5.2 
MonoHexCer(809) 27.9 12.5 14.4 7.2 0.5 3.6 
MonoHexCer(811) 19.4 13.5 17.4 10.9 0.9 5.2 
Cholesterol 4.9 12.7 14.8 7.6 3.0 3.7 
Cholesterol Ester NA 33.0 33.7 7.2 NA 19.4 
24S-hydroxy-cholesterol NA 15.8 23.4 17.2 NA 9.3 
 22R-hydroxy-cholesterol NA 12.8 21.0 16.6 NA 7.5 
7-dehydrocholesterol 4.2 8.0 20.2 18.6 4.9 7.0 
27-hydroxy-cholesterol 2.8 15.5 22.2 16.0 7.9 8.4 
Median    8.8 1.0 3.8 Na is the number of samples required to estimate the underlying homeostatic set point 
within ±	 15% with 95% confidence. CVG and CVI with NA denote variance is 















Figure 5.5 Diagram depicting the index of individuality (II) for erythrocyte lipids.  
It is observed that majority of the lipid species found in the erythrocyte has an index >0.6, 
thus supporting the use of population reference interval. Though it should be noted that most 
of the lipids fall in the grey area (0.6<index<1.4), so care should be taken while using these 
lipids as biomarkers in a population study. Note that sterol in this diagram only represents 
cholesterol as the sterol derivatives have value that is greater than what the diagram can 
represent. Based on further investigation, this is due to imprecision of measurement of the 
analytical platform as shown in Table 5.2. 
 
5.4 Discussion  
5.4.1 Aim and rationale  
The aim of this study was to characterize the BV of the erythrocyte lipidome 
in healthy individuals over 120 days. In general, characterization of BV in the 
erythrocyte of healthy individuals is highly important as this step in biomarker 
discovery will allow one to determine if the signature biomarker does indeed 
reflect a difference in metabolic end point when compared between healthy 







































Despite being morphologically homogenous in general, a clear source of BV 
has been established in several components of the erythrocytes. They include 
the hematocrit, hemoglobin concentration, erythrocyte volume fraction, mean 
volume [140, 141], cholinesterase activity [142] and the level of HbA1c [143]. 
Nonetheless, there is a common yet unsubstantiated belief that erythrocytes 
are extremely suitable as source of biomarkers due to their high stability in the 
circulation. These cells are believed to be non-dividing and have a relatively 
stable cell membrane during their 120 day lifespan in the circulation [66]. In 
fact, little or no turnover of the plasma membrane is present as the mature 
erythrocyte completely loses its ability to produce lipids de novo [65, 66]. 
Moreover, even if remodeling of the membrane lipids does occur, it is often 
slow as the activities of these enzymes are low in the mature erythrocytes [65, 
66]. However, up to today, there exists no study of BV in the erythrocyte 
lipidome. Hence, characterization of BV in the erythrocyte lipidome will be of 
great value in the field of biomarker discovery. 
 
5.4.2 Importance of learning the nature of BV in healthy individuals 
and its application in biomarker discovery 
The development of robust analytical technologies in mass spectrometry has 
allowed the identification of metabolic signatures (including lipids) as 
potential biomarkers for the diagnosis and prognosis of diseases with great 
sensitivity and specificity [144]. Due to the ease of measuring a 
comprehensive number of metabolites in a single run, the search for 
biomarkers became more technological-driven rather than hypothetical-driven 
[145]. Despite this, it is undeniable that good precision of the analytical 
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platform [4, 81, 138, 139] and strong emphasis of pre-analytical processing 
(i.e., collection, handling and storage) [146-148] have allowed major progress 
to be made in the development of biomarker discovery in recent years [144].  
 
However, the identification of a reliable signature biomarker still requires 
much work. Many investigators have described the process of biomarker 
discovery as “searching for a needle in a haystack” [145, 149-151]. Indeed, 
this analogy is certainly right, as the hunt for biomarkers is often a signature 
that is only slightly different (abnormal) when compared to the normal state 
[145]. To complicate matters, the definition of normalcy in healthy, non-
diseased individuals, is being influenced by a multitude of exogenous and 
endogenous attributes such as age, gender, ethnicity, diet, cyclical rhythms, 
physical activities and homeostasis [96]. As a consequence, the study of 
between-subjects and within-subject BV in healthy individuals will be very 
useful, as this knowledge can then be used in designing the appropriate 
biomarker experiment (i.e., population study), requesting for the correct 
samples (i.e., single or serial sampling) and possibly helping in the 
interpretation of the data [133].  
 
5.4.3 Establishing technical variation and BV in the erythrocyte 
lipidome 
The present study first set out to measure the CVP and CVA of a 
comprehensive group of erythrocyte lipids to determine the precision of 
sample processing and the analytical instrument respectively. It is well 
accepted that imprecision from the analytical platform cannot be entirely 
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eliminated. Nevertheless, these values are important to keep in mind since a 
result is of no value if the imprecision is rendered dangerously unreliable 
[152]. Based on the estimated CVA, the majority of the lipid species measured 
in the study was <10%, well within the FDA guideline of <20% for 
acceptability in analytical precision. Likewise, the CVP value of each lipid 
(inclusive of the estimates of CVA) was assessed to examine variability due to 
sample processing. Since the observed CVP was similar to that of CVA, this 
suggests that good laboratory practice was implemented in the study and that 
the bulk of technical variability is contributed by the imprecision of the 
instrument. As a consequence, pre-analytical imprecision is assumed to be 
negligible and technical variation in the study is solely represented by the 
instrumental imprecision as measured by CVA. To ensure high quality of data, 
only lipids with CVA of <20% were used for further analysis, as similar values 
were reported when using LC-MS (9-18%) [138] and shotgun-MS (10%) 
[139]. 
 
The between- and within-subject BV of erythrocyte lipids in a homogenous 
group of resting healthy individuals were examined across 120 days. These 
subjects were Chinese, male and aged between 30-39. Their erythrocyte 
samples were taken after an overnight fast (overnight fasting is the typical 
condition used in biomarker studies to eliminate any possibility of dietary 
effects). Based on the findings, a diverse range of within- and between-subject 
variation in the erythrocyte lipids was observed. Generally, the between-
subject variation (CVG) is larger than that of the within-subjects (CVI) in 
majority of the erythrocyte lipids. This observation is similar to the BV of 
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many clinical chemical analytes where the intra-individual variation is less 
than that of between-subject variation (CVI < CVG) [96]. Interestingly, 
cholesterol and the majority of PEs, both major components of the erythrocyte 
membrane, had a higher within-subject variation (CVI) as compared to 
between-subject variations (CVG). This is not likely to be due to analytical 
imprecision as CVA can only account for 5.2 - 9.6% of the variance in these 
lipids. As such, the underlying reason for this observation is still unknown. A 
possible explanation for this may be because both PEs and cholesterol are 
known to have major structural role in the membrane. Cholesterol is known to 
influence the fluidity of the membrane due to its rigid sterol structure [153]. 
PEs, on the other hand, are cone-shaped lipids and have been shown in vitro to 
form non-lamellar membrane structures which modules the membrane 
curvature [154]. Together, they thus determine the permeability and stability 
of the erythrocyte [155]. Hence, it is likely that these lipids vary more often to 
compensate for the required permeability and stability of the membrane of the 
erythrocytes depending on the state of the individual.  
 
In contrast, the within-subject variation (CVI) of all PIs is smaller than the 
between-subject variations (CVG). This observation is highly intriguing since 
PIs are known to be able to phosphorylate singly or in combination to generate 
secondary messengers involved in signal transduction and membrane 
trafficking [156, 157]. As such, being highly conserved and less variable 
within an individual makes remarkable sense as the activation of PI signaling 
should not take place constantly but only at times of need. Admittedly, this is 
still a hypothesis and not a theory.  
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5.4.4 Usefulness of II in biomarker development 
The measure of within- and between-subjects BV has huge implications to the 
II which is the ratio between CVW to CVG [133]. There are two main uses for 
II. First, it is an important indicator to determine the usefulness of a 
population-based reference interval in identifying disease based on various 
analytes [96, 158]. As shown in Figure 5.3, paradoxically, an analyte is said to 
have marked individuality when its index of individuality (II) is low or vice 
versa [96, 159]. In the case when an analyte has high individuality (low index 
of <0.6), detection of a disease using a population-based reference interval is 
less sensitive as the within-subject variation is small resulting in an 
individual’s result spanning within a very narrow range of the population 
reference interval [134, 160]. As illustrated in Figure 5.6 (A), this will mean 
that an individual’s (i.e. Individual Y) metabolite level would have a high 
chance of being measured to be within the population mean of the healthy, 
even though the level of his metabolite is actually considered diseased with 
respect to himself. Hence, the use of a population reference interval is deemed 
to be unsuitable for any metabolite with high individuality (index of <0.6) as 
that will lead to a false negative. In contrast, when the individuality of the 
metabolite is low (index of >1.4), the conventional use of a population 
reference interval will be highly useful [134] as the measured level of the lipid 
in the individual will be in the range of the population interval. For analytes 
with II between 0.6 to 1.4, it has been suggested by Walton et al. [137] that 
the population-based reference interval could still be used but with much 
caution. With respect to the II of the erythrocyte lipidome, most of the 
erythrocytes lipids have an index of >0.6. This suggests the use of a 
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population based reference interval when looking for a signature biomarker in 
the erythrocyte lipidome. It should be noted though that some lipid species do 
have high individuality (index of <0.6) and should thus be excluded in a 


















































Figure 5.6 Hypothetical illustration of lipid metabolite with high or low individuality. 
(A) Hypothetical illustration of lipid metabolite with high individuality (index of <0.6). It 
would be inappropriate for lipids with high individuality to use a population-based reference 
interval to determine the health status of an individual. As depicted in the diagram, the within-
subject variation of the lipid metabolite in individual Y is inside a narrow range of the 
population-based reference interval. As a result, even when the level of lipid metabolite in 
individual Y is changed to a diseased level, this may not be detected, as it would still be 


























Another application of II is to suggest if a single or serial measurements will 
be required in evaluating a change in an analyte of an individual [160]. Based 
on the II, some lipids measured in the erythrocyte lipidome have very low 
individuality (high index ranging from 2.7 to 4.2). This suggests that these 
lipids have a higher within-subject variation and thus multiple sampling in an 
individual will be required before the true value of the lipid in that subject is 
measured. This is well illustrated in Figure 5.6 (B) where multiple 
measurements are required before a proper estimate of the lipid level could be 




























































Figure 5.6 Hypothetical illustration of lipid metabolite with high or low individuality. 
(B) Hypothetical illustration of lipid metabolite with low individuality (index of >1.4). As 
depicted in the diagram, lipid metabolites with low individuality tend to have high within-
subject variation (as shown in individual X). This would mean that a single measurement 
would not be sufficient to accurately estimate the metabolite’s true mean in an individual thus 

























In almost all biomarker studies, only one sample at a single time point is 
collected from an individual. As a result, this reflects a very narrow snapshot 
of an individual in his entire lifespan [161, 162]. This becomes a concern since 
the single point sample may not be a good representation of the true 
homeostatic set point for lipids with low individuality (high index of >1.4). 
However, the logistics involved in all aspects of a biomarker study will 
become much more complex when the inclusion of serial measurements is 
required. Not only will it demand more time to complete the collection of 
samples, it is highly possible that the dropout rate of the volunteers will 
increase. Moreover, there will be added difficulty in analyzing a larger number 
of samples. Furthermore, added complexity in the data analysis will also be 
unavoidable.  
 
Nevertheless, it is not the intention of the author to criticize or discourage 
investigators of biomarker studies. Rather, the point was made to provide 
rationale to support a suggestion. If a particular study is unable to recruit 
volunteers for serial measurement (i.e., ongoing studies or completed studies), 
the study can still be valid as long as there is substantial number of samples 
from both healthy and diseased since a good estimate of the population 
reference interval can still be derived. When it comes to the actual 
diagnostic/prognostic use of the signature lipid biomarker, multiple samples 
should be taken from an individual to properly estimate their true mean for 
determination of the clinical outcome. Based on the finding of this study, most 
erythrocyte lipids require at least 4 measurements (on different days) before 
the accurate homeostasis mean of an individual can be determined. 
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5.4.5 Limitations 
At this point in time, this study provides a strong framework to understanding 
BV in the erythrocyte lipidome. However, much work needs to done to 
validate the estimates of CVA, CVG, CVI and II established in the study. 
Despite the fact that pre-analytical variation was kept to a minimum and strict 
analytical precision criteria based on FDA guidelines for metabolomics study 
(CVA <20%) was adopted, bias may still be present in some of the measured 
lipid species. Examples of such concern are clearly seen in the sterol 
derivatives (i.e., Cholesterol ester, 24S-hydroxy-cholesterol, 22R-
hydroxycholesterol, 7-dehydrocholesterol, 27-hydroxy-cholesterol) whereby 
their II is exceptionally high. Through close inspection of these values, it is 
highly likely that the large II is confounded by analytical variation. The CVA 
of these lipids was observed to be generally higher as compared to the rest 
since they are of lower abundance in the erythrocyte lipidome. As a result, 
detection of these lipids is less precise. Evidently, MS with a better sensitivity 
should be used in detection of these low abundant lipid species in order to 
obtain a more desirable performance.  
 
Furthermore, while pre-analytical variation in this study is considerably low 
due to good laboratory practice and execution by skilled personnel, sample 
preparation still remains a source of high variability [163]. Hence, 
consideration in using a robotic-assisted system [40] to help streamline sample 
processing to make it less person-dependent and of a higher accuracy can also 
be taken to improve the study. Moreover, pre-analytical precision in this study 
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only measures the contribution in sample processing. Admittedly, variability 
involving storage and sampling should have also been determined.  
 
5.5 Conclusion 
The development of MS has enabled the advancement of biomarker studies in 
the identification of potential prognostic and diagnostic markers for various 
diseases. Much effort has already been put into improving precision of the 
analytical platform to ensure high quality data to be generated through MS. 
However, it is undeniable that the majority of the investigators (us included) 
have largely neglected the consideration of BV even though it affects the 
reliability of the biomarker. As a consequence, the progress of biomarker 
studies is hampered. While thousands of MS-biomarkers are identified each 
year, only a small number make it to clinical practice [122].  
 
There is a clear need to study the BV of the erythrocyte lipidome for 
application in biomarker studies. Popularity of lipid-based biomarkers in the 
erythrocyte membrane is emerging and can be seen in the studies of diet [164, 
165], longevity [166], and diseases [167, 168]. To highlight its presence, 
Lipinutragen Srl, a spin-off initiative company of the Italian National Council 
of Research (CNR) has developed FAT PROFILE®, a method which only 
focuses on evaluation of the fatty acids found on the phospholipids of the 
erythrocyte membrane. Even so, BV is also not well studied in their 
methodology (http://www.lipinutragen.it/en/Fat_profile.asp?sez=cose).  
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Evidently, the estimates of CVA, CVG, CVI and II can provide crucial 
information for investigators when designing biomarker experiments with a 
clear understanding of the requirements of the study. In brief, investigators can 
set their analytical goal based on the CVA, evaluate the usefulness of a 
population-based study in yielding reliable signature biomarker and determine 
an estimate of the required number of samples from an individual to properly 
determine their true mean [133]. 
 
Currently, this is the first study that characterizes the BV of a comprehensive 
list of erythrocyte lipids in the lipidome. Nonetheless, the list is incomplete as 
it is covers only males, aged between 30-39 and of Chinese ethnicity. 
Therefore, similar works targeting different lipid species, age group, gender 
and ethnicity should be performed to have a complete picture of BV in the 
erythrocyte lipidome. Collection of such information, inclusive of other 
biological fluids, into a database will definitely provide a great advantage for 
any investigator interested in lipidomics biomarker discovery.  
 
There is no doubt that procurement of such BV information will be highly 
useful. However, a considerable amount of time and effort is required to 
obtain this information, especially in the estimation of within-subject variation 
(CVI). Fortunately, precedents in BV for clinical analytes have shown that 
there is strong constancy for the estimates of CVI regardless of the number of 
subjects, the period of the study, the methodology, and the country in which 
the study was conducted [134]. An example of such an observation can be 
seen in serum sodium and serum urea [134]. This is expected, as Callum G. 
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Fraser puts it (2001) [134], “this constancy is hardly surprising because 
within-subject biological variation is the quantitative estimate of homeostasis 
in a single animal species – human!”. Hence, there is really no need for every 
laboratory to repetitively generate this information as long as the precision of 
their analytical platform is within a similar range. Instead, investigators should 
work together towards building a database that covers the BV of a 
comprehensive list of lipids from various biological fluids. This information 
can then be shared with fellow investigators and used for better execution of 
biomarker studies.  
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6.1.1 The necessity of diagnostic biomarker for schizophrenia 
Schizophrenia is a major mental disorder characterized by psychosis, negative 
symptoms and neurocognitive deficits [169]. Approximate of 1% of the 
population in Singapore [170] and worldwide develops this mental disorder 
during their lifetime [171, 172]. It tends to strike individuals during late 
adolescence or early childhood [173] between the age of 15 to 35 years old 
[169]. Interestingly, gender differences have also been well-established in 
schizophrenia [174] in which the onset happens earlier in males than females 
[175, 176]. Despite its relatively low lifetime prevalence, this mental disorder 
is deemed to have an enormous impact in terms of economic burden [177]. In 
the case of Singapore, schizophrenia is ranked ninth for burden of disease 
(Whole Health Organization, WHO) [177].  
 
With more than three decades of painstaking research, the etiology of 
schizophrenia however, remains unclear [178, 179]. Currently, no biologically 
validated laboratory methods are available for clinicians to use in the routine 
diagnosis of the disease [60]. Diagnosis and monitoring of the disease is 
purely based on subjective clinical observations and patients’ medical history. 
The shortcomings in such a diagnostic method is clear, as individuals who are 
at risk are essentially not definitively identified while prodromal individuals 
may be missed out [180]. Furthermore, symptoms of bipolar and 
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schizophrenia are often similar and thus poses a hindrance for clinicians in 
distinguishing between the two [181]. Evidently, the presence of biomarkers 
in the form of genes, protein, and other molecules, or morphological 
characteristics, would therefore be desirable for the diagnosis of schizophrenia 
and its related psychoses [182]. Current ongoing research efforts to develop 
biomarkers aiding in the diagnosis and prognosis of this mental disorder are 
apparent.  
 
6.1.2 Progress of existing potential gene and protein biomarkers of 
schizophrenia   
With genomic and proteomic techniques, much progress has been made in the 
discovery of novel schizophrenia biomarkers. Genetic studies can help to 
identify genes which reveal an individual’s predisposal to certain diseases. 
This is no different in the case of schizophrenia. Through a series of family 
and twin studies, genetic effects on the development of schizophrenia has been 
well demonstrated [183-186] though its mechanism remains obscure [187]. 
Nevertheless, this supports a highly heritable component in schizophrenia 
[188, 189]. 
 
Evidence of strong hereditability highlights a major role in inherited genetic 
variants, which can be used in studying the etiology of schizophrenia [183-
186]. Based on genome-wide association study (GWAS), it has been observed 
that half to a third of genetic risk of schizophrenia is linked to common alleles 
genotyped in GWAS [188]. As a consequence, the Schizophrenia Working 
Group of the Psychiatric Genomics Consortium (PGC) was created, as GWAS 
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are believed to be a strong potential tool for understanding the biological 
underpinnings of schizophrenia [188]. Indeed, the largest genetic study of 
schizophrenia to date, conducted by PGC has identified at least 108 
independent schizophrenia-associated loci from a compilation of published 
and unpublished GWAS data [188]. Notably, association involving genes of 
the dopamine receptor D2, glutamatergic neurotransmission, synaptic plasticity 
and immune dysregulation are most implicated in schizophrenia [188].  
 
No doubt such candidate genes show strong epidemiological association in 
schizophrenia but when it comes to relating the disease to these genes, one has 
to do it with caution due to certain limitations of genomics study. Firstly, 
many innate variants, for instance, gene-gene or gene-environment 
interactions and variability in schizophrenic patient demographics are not 
accounted for. Moreover, the relationship between genes and phenotypes may 
be difficult to establish since it is the varying effects of multiple gene 
interactions that lead to a wide spectrum of schizophrenic symptoms [190]. 
Evidently, even with the presence of high hereditary concordance found in 
twin and family studies, together with strong epidemiological association of 
certain genes to this disorder [183-185, 191], so far, no single gene or genetic 
variant can be determined as the bona fide gene for schizophrenia or at least 
not with as much certainty as other multi-gene associated diseases (i.e., 
Alzheimer’s disease) [192]. This may not come about as surprising, as the 
heterogeneous nature of schizophrenia is constantly highlighted by various 
investigators [189, 193-195]. 
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Similarly, proteomics studies have been extensively carried out in search of 
useful biomarkers. The most mentionable being a putative serum blood-based 
biomarker called VeriPsych. This putative marker is created by company 
PsyNova (founded by Professor Sabine Bahn), which measures a total of 51 
blood analytes of small molecules and proteins in the serum that aids in the 
diagnosis of schizophrenia [196, 197]. These proteins can be categorized into 
three distinct functional classes belonging to involvement in 1) inflammation 
and oxidative stress, 2) molecular transport, 3) clotting factors, hormones and 
growth factors [49, 198]. The performance of this biomarker has high 
specificity and sensitivity. In fact, VeriPsych was available on the market in 
2010 but later withdrawn, as evidence of validation was not shown in this 
diagnostic test. This includes not having rigorously tested its predictive power 
using independent cohorts, by independent laboratory and personnel [197]. 
Also, the question of being specific to the diagnosis of schizophrenia is still 
uncertain as it is well established that schizophrenia and bipolar/depression do 
share common molecular neuropathology [197, 199, 200]. Nevertheless, 
continuous efforts have been made by PsyNova and Bahn’s group to address 
these limitations [49, 201, 202]. However, it is still hard to verify if all the 
proteins/analytes detected with alterations have a direct link with 
schizophrenia. Hence, there is still room for investigation, giving others the 
task of exploring more specific biomarkers for the diagnosis of schizophrenia. 
 
6.1.3 Application of lipidomics in the diagnosis of schizophrenia   
Undeniably, global genomics and proteomics research complement each other. 
They can provide a multitude of data regarding the identification of 
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differentially expressed proteins as well as possible post-translational 
modifications that might be related to the disease [60]. Regrettably, 
information on the two alone cannot complete the understanding of the 
pathophysiology of schizophrenia. Schizophrenia, is known to be a psychiatric 
disorder primarily of the central nervous system (CNS) [202]. Since a major 
component of the CNS consists of the brain, where 50% of its dry weight is 
made up of lipids, in particular phospholipids and cholesterol [181, 203-205], 
it is thus relevant for one to examine this mental disorder from a lipidomics 
perspective. This association is not something out of the ordinary as many 
metabolic changes in the brain have been identified and linked to psychiatric 
disease pathology, including schizophrenia [181, 206]. 
 
A decade worth of research on the post-mortem brains of schizophrenic 
patients have revealed accumulating evidence of abnormalities in the 
prefrontal cortex, thalamus, hippocampus, anterior cingulate and cerebellum 
being associated with schizophrenia [203, 207, 208]. This is accompanied by 
changes in key functional systems, which contribute to the pathogenesis of 
schizophrenia. They include areas in signal transduction, neurotransmission, 
antioxidant systems and immune functions, where phospholipids and their 
constituent fatty acid components are required in provision of scaffolding to 
allow for normal functioning [209-211]. Furthermore, evidence for increased 
abnormality in the composition and metabolism of cell membrane 
phospholipids in the brain are also reported [203]. This is in great agreement 
with Horrobin’s postulation of a membrane phospholipid concept in the brain 
of schizophrenic patients [212] in which the aberration of the membrane 
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phospholipids could be attributed to the activity of phospholipase A2 (PLA2), a 
metabolic enzyme of phospholipids [213]. Over activity of PLA2 in the brain 
has long been reported in these mental patients [179, 214, 215]. Evidently, the 
strong association of schizophrenia with lipids in the brain thus makes 
lipidomics a perfect tool for the elucidation of diagnostic biomarkers for this 
mental disorder. 
 
6.1.4 Erythrocytes as source of biomarker in schizophrenia 
Although primarily considered as a disorder of the CNS, there is also 
substantial body of evidence to suggest that schizophrenia may have 
peripheral manifestations [49, 212]. Strong support of analogies between 
peripheral tissues and brain tissues derived from previous post-mortem studies 
have demonstrated that lipid profiles of membrane phospholipids, glycolipids 
and PUFA in the brains of deceased patients with schizophrenia to be similar 
to those seen in the peripheral cell membranes [52]. Lipid analyses of post-
mortem brain of schizophrenic patients showed a decrease in levels of PUFA, 
PE, PC, SM, galactocerebrosides and an increase in the levels of PS and PI in 
postmortem brains of schizophrenic patients [52, 216]. Most importantly, 
some of these changes were replicated in peripheral tissue such as the 
erythrocytes, platelets and fibroblasts [52]. Likewise, an abnormally high level 
of PLA2 was also found to be present in the blood of schizophrenic patients 
[217]. Taken together, this highlights the prospect of using blood cells as a 




Amongst the various types of blood cells, erythrocyte holds the most potential 
as candidate in biomarker discovery as the lipid pattern and fatty acid 
composition of this cell strongly reflects that of the neuronal membrane in the 
brain [218-220]. Evidence of morphological abnormalities have been reported 
in surface architectonics analysis of erythrocytes in schizophrenic patients 
[221]. It was observed that functionally biconcave discocytes were found to be 
significantly decreased in non-pharmacologically treated patients with 
paranoid schizophrenia, followed by a concomitant increase in the percentages 
of abnormal erythrocytes [221]. Since shape and stability of erythrocytes are 
known to be conferred by membrane phospholipids [69], it is therefore highly 
probable to find compositional aberration in the erythrocyte membrane which 
could act as biomarker for this mental disorder. Moreover, these cells are also 
ideal targets as the mature erythrocytes do not contain any intracellular 
membrane compartments other than its plasma membrane component [65]. 
With a relatively stable and non-diving lipid membrane [65, 66], any aberrant 
lipid pattern that may be established must therefore originate from the lipid 
bilayer of the erythrocyte. More importantly, any deviation from the normal 
lipid composition of the erythrocyte membrane can then be used as a 
biomarker to provide an indication of the disease state in a person.  
 
Furthermore, recent literature has shown deficits in the fatty acids of the 
erythrocyte membrane with respect to individuals who are at ultra high-risk 
(UHR) of psychosis. The investigation led by Amminger et al. [222] in 2012, 
has connected the strong evidence of PUFA abnormalities in individuals with 
schizophrenia to neuroleptic-naïve UHR individuals who subsequently convert 
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to having a psychotic disorder. A decrease in nervonic acid (NA) was found to 
be present in the erythrocyte membrane of help-seeking UHR individuals who 
subsequently converted to having a psychotic disorder. This observation not 
only highlights the strong association of erythrocyte lipids with the 
development of psychosis but also led investigators to propose the reduction 
of NA as a potential prognostic marker in the prediction of psychosis. A 
follow-up study conducted by the same group of investigators 2 years later 
[223], extended their work not only through the evaluation of more fatty acids 
in the erythrocyte membrane but was also able to demonstrate the relationship 
between erythrocyte membrane fatty acid to cognitive functions in 
neuroleptic-naïve UHR psychotic individuals. Through the study, it was found 
that the severity of cognitive symptoms and function in UHR individuals was 
associated with high level of omega-9 eicodenoic and erucic acids and lower 
level of omega-3 DHA in the erythrocytes [223].  
 
Due to the outcome of these findings, alternative treatment to reduce or delay 
transition rate to psychosis using intervention with long chain omega-3 fatty 
acid was thus conducted [224, 225]. It was found that supplementation with 
omega-3 fatty acid greatly improved cognitive function and reduced the 
symptoms of psychosis [224, 225]. Though the underlying mechanism of 
action with respect to omega-3 fatty acid is unclear, it has been suggested that 
the supplementation provides neuroprotectivity by reducing neuro-progression 
due to oxidative damage and excitotoxcity, while also delivering the required 
resources for neural membrane plasticity [226]. Safety concerns regarding the 
use of omega-3 fatty acid have also been examined [227] and is shown to be 
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generally safe even at high dosages, except for the possible increase of 
bleeding time and mild gastrointestinal symptoms [228].   
 
6.2 Rationale 
Strong evidence of lipid association in schizophrenia has already lead many 
investigators to examine the erythrocyte lipid abnormalities in these patients. 
Despite accumulating evidence of such studies, certain gaps still persist in our 
understanding of the erythrocyte membrane lipid abnormalities in 
schizophrenia as the detailed examination of these lipids has yet been done on 
a comprehensive scale. Indeed, it is known that changes in levels of fatty acids 
and phospholipids are found within the erythrocytes membrane [213, 229, 
230]. Nonetheless, the existing data are occasionally contradictory, not only 
because total lipid levels (rather than subtypes) were measured in most of the 
studies, but also due to methodological constraints resulting from small 
sample sizes and the use of lower resolution techniques [213, 229].  
 
With supplementary evidence through findings in Chapters 4 and 5 that the 
erythrocyte lipidome serves to be a good target for biomarker discovery due to 
its stability and overall suitability in population-based biomarker studies. The 
aim of this study is to therefore employ a high sensitivity and specificity, 
targeted mass spectrometry approach based on MRM to allow a large-scale 
characterization and quantification of various lipid classes found in the 
erythrocyte membrane of schizophrenic patients and healthy controls. This 
was done in hopes to identify a signature lipid biomarker within the 
erythrocyte membrane, which could act as a diagnostic tool for schizophrenia 
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in a clinical setting. Also, to provide some valuable insights to biomarker 
discovery of the elucidated lipid signature based on knowledge of biological 
variation (BV). 
 
6.3 Material and methods 
6.3.1 Study design and subjects 
This case-controlled study compared schizophrenia patients with healthy 
controls. Inclusion criteria for cases were patients aged 21 to 50, with 
diagnosis of schizophrenia. Cases were recruited from the Institute of Mental 
Health in Singapore (IMH, Singapore). The diagnosis of schizophrenia was 
established using the Structured Clinical Interview for DSM-IV-TR Axis I 
Disorders (SCID-I). Cases were excluded if they had a diagnosis of mental 
retardation or substance dependence syndrome. Controls were similarly aged 
21 to 50 and were recruited from the community and defined as persons with 
no history of psychiatric disorders as assessed by the SCID-I (non-patient 
edition).  
 
Detailed demographics regarding gender, ethnicity, BMI, smoking status, 
education level, socio-economic background, diet (i.e., fatty fish intake) and 
history of psychotic illness in first/second degree relatives were also recorded 
in this study. Metabolic syndrome (MetS) was also determined between the 
patients and controls based on criteria set by the American Heart Association 
(AHA) and National Heart, Lung and Blood Institute (NHLBI). The criteria 
include elevated TG, elevated blood pressure, elevated fasting glucose, 
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abdominal obesity, and reduction in HDL [231]. Individuals fulfilling at least 
three of the criteria were considered to suffer from MetS.  
 
The study was approved both by the institutional review boards of the Institute 
of Mental Health (IMH, Singapore) and the National University of Singapore 
(NUS). All participants or their legal guardians gave written informed consent 
for this study. 
 
6.3.2 Scanning electron microscopy (SEM) of different erythrocyte 
morphologies 
Prior to lipid analysis, an independent group consisting of ten schizophrenic 
patients and ten healthy controls had their blood drawn for erythrocyte 
morphological studies. General demographics of these individuals were 
tabulated and found in Supplementary Table S4. Total blood samples taken for 
SEM examination of the erythrocyte morphology were processed immediately 
to avoid potential structural defects caused by additional handling. The 
samples were processed within 1 hour of collection. Total blood was fixed 
with 2.5% glutaraldehyde in PBS for approximately 16 hours at 4°C. Samples 
were rinsed twice with PBS. The process of fixation was carried out by gentle 
mixing of 1% osmium solution (pH 7.4) with the sample and incubating at 
room temperature for 30 min. Samples were washed twice with deionized 
water and resuspended in deionized water. A few drops of sample suspension 
were placed on a poly-l-lysine-coated cover slip and left to dry for 10 min. 
The cover slip was rinsed once with deionized water prior to dehydration 
using a series of ethanol solutions at room temperature (5 min in 50% ethanol, 
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10 min in 75% ethanol, 10 min in 95% ethanol, and three times for 10 min in 
100% ethanol). Cover slips were transferred to a critical point dryer (BAL-
TEC CPD 030, Balzers, Liechtenstein), where liquid carbon dioxide was used 
as a transitional medium to replace the ethanol in the sample. At the end of the 
fluid exchange, liquid carbon dioxide was vaporized and released by raising 
the temperature to 38°C.  The dried samples were then transferred to a sputter 
coater (BAL-TEC SCD 005, Balzers, Liechtenstein), where the dehydrated 
samples were coated with 15-nm layer of gold. The samples were examined 
using a scanning electron microscope (JEOL JSM-5600LV, Tokyo, Japan).  
Ten images of each sample were taken at 750X magnification, 10 kV 
acceleration voltage, and 30V spot size. After acquisition of all images, the 
images were coded and then counted for different erythrocyte morphologies 
by a blinded assessor.  
 
6.3.3 Sample collection and isolation of erythrocytes 
Subjects involved in lipid profiling of their erythrocyte membrane provided a 
sample of fasting venous blood, drawn into EDTA-containing Vacutainer 
tubes. Erythrocytes were isolated from the whole blood sample and mixed 
with PBS. An aliquot of the homogenous erythrocyte sample was used for Hb 
measurement while the rest was stored in -80oC for lipid extraction. Personnel 
involved in the experimental protocol were blinded to the diagnosis of each 





6.3.4 Hb measurement 
The concentration of Hb in each sample was measured using Coulter HmX 
Hematology Analyzer (Beckman Coulter, Inc., California, USA) with 
autoloader. Triplicate counting was performed in each sample to ensure high 
accuracy of the reading.  
 
6.3.5 Quality control 
Quality control measures were implemented for each batch of samples. In 
brief, QC samples and two to three R samples were periodically injected in 
each batch of run to determine analytical and pre-analytical variation, 
respectively. The details were described in Chapter 3.3. 
 
6.3.6 Quantification of phospho-, sphingo- lipids and sterols using mass 
spectrometry  
Erythrocytes were isolated and their lipids were extracted using the modified 
Bligh and Dyer’s method [112] as described in Chapter 3.2. Analysis of the 
respective classes of lipids was also described in Chapters 3.4, 3.5 and 3.6.  
 
6.3.7 Data processing and statistical analysis 
MRM data were extracted using Analyst Software (version 1.4.2, Applied 
Biosystems) and converted into text format. The data was normalized by 
respective internal standards. LOESS batch correction was performed to 
remove batch-to-batch variation. The details of the correction were described 
in Chapter 5.2.6.1. Following which, median fold normalization was also 
performed to remove any bias in differential amount of starting material. Any 
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samples that were found to deviate strongly from the mean would be treated as 
outliers and removed. Heatplots were generated through MATLAB (version 
7.0.4, MathWorks Inc., Natick, MA, USA) or software R (http://www.r-
project.org). PCA plots were generated using software R.  
 
6.3.7.1 Comparison of demographics and morphological differences  
Statistical analyses of demographic, clinical variables and morphological 
differences were performed using SPSS (SPSS Inc., Chicago, IL, USA). 
Significant differences between categorical variables were determined using 
the chi-squared test. Differences between continuous variables were 
determined using the Student’s t-test or Mann-Whitney U test.  
 
6.3.7.2 Lipid differences and covariants 
Group comparison was evaluated using ANOVA and adjusted using 
Benjamini-Hochberg correction to control for false discovery. As shown in 
Table 6.1, the patient and control group was not well matched in factors such 
as gender, BMI, smoking stats, educational level, socio-economic background, 
diet (fatty fish intake) and MetS status. As a result, the group effect may be 
confounded by these demographic covariants. In order to address the 
possibility of confounders, relevant covariants were first identified and 
grouped together. After which, ANOVA, was once again used to determine 




Linear discriminant analysis was carried out using SPSS (SPSS Inc., Chicago, 
IL, USA). The final model generated was evaluated for sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and 
accuracy. Leave-one-out cross validation was also done to determine the 
reliability of the classifier.  
 
6.4 Results 
6.4.1 Subjects and socio-demographic data  
A total of 100 patients and 300 controls were recruited for this study. Detailed 
demographic data of all the participants are shown in Table 6.1. The majority 
of the participants in the study were of the same origins where 85% of the 
patients and 81.3% of controls were Chinese. The mean age of patients was 
36.63 (SD 7.52) and the mean age of controls was 34.85 (SD 8.22). There 
were no significant differences in age or ethnicity between the patients and 
controls. However, a significant difference was found in gender distribution 
between the patients and controls, where the proportion of male patients was 
at 55% while the male controls was at 66%. In terms of BMI, patients were 
found to have a BMI of 25.87 (SD 5.31) while the BMI of controls were 24.12 
(SD 4.47). A significant difference was observed between the two groups. It 
was noted that the BMI for both patients and controls were higher than the 
healthy range (BMI: 18.5 - 23). MetS in the patients and controls was also 
determined. It was found that MetS was significantly higher in patients (48%) 
as compared to the controls (18.7%). Smoking history was reported in 31% of 
the patients and 8.7% of the controls. A clear difference in frequency of 
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smoking was also found, where patients smoked more often. The 
socioeconomic background between the two groups was evident as seen in 
their educational level, occupation and type of residence they lived in. The 
majority of the controls had university education, were professionals and more 
had the ability to live in private housing as compared to the schizophrenia 
patients. This discrepancy in socioeconomic background was also observed in 
their diet whereby fatty fish intake by the control group was higher than the 
patients. Amongst schizophrenic patients, the average duration of the patients 
was 12.2 years (SD 7.2). These patients were chronic anti-psychotic drug 
users treated with for an average duration of 12.1 years (SD 7.1). The mean 
daily antipsychotic dose in chlorpromazine equivalents was 295.8 mg (SD 















Table 6.1 Demographics of the volunteers who participated in the study. 	   Controls Patients p-value 
N 300 100 	  
Gender (male/female) 159 (53%)/141 (47%) 
66(66%)/34 
(34.0%) 0.023* 
Age (years) 34.85(8.22) 36.63(7.52) 0.066 
BMI 24.12(4.47) 25.87(5.31) 0.001** 
MetS# present 56(18.7%)	   48(48%)	   0.0001*** 
Ethnicity 	   	   0.945 
chinese 244(81.3%) 85(85%) 	  
malay 24 (8%) 7(7%) 	  
indian 28 (9.3%) 8(8%) 	  
others 4 (1.3%) 0(0%) 	  
Non Smoker/ Smoker 274 (91.3)/26 (8.7%) 
69(69%)/31 
(31%) 0.0001*** 
Smokers classification 	   	   0.0004*** 
casual smoker 
15(57.7%) 6(19.4%) 	  (smoke 1-5 cigarettes/day) 
moderate smokers 
8(30.8%) 6(19.4%) 	  (smoke 6-10 cigarettes/day) 
frequent smokers 
3(11.5%) 19(61.3%) 	  (smoke more than 11 cigarettes/day) 
Highest education level 	  	   	  	   0.0001***	  
nil 0(0%)	   2(2%)	   	  	  
primary 20(6.7%)	   10(10%)	   	  	  
secondary 53(17.7%)	   41(41%)	   	  	  
junior college 21(7%)	   13(13%)	   	  	  
polytechnic 77(25.7%)	   21(21%)	   	  	  
university 103(34.3%)	   5(5%)	   	  	  
vocational training 20(6.7%)	   8(8%)	   	  	  
others 6(2%)	   0(0%)	   	  	  
Occupation 	   	   	  
professional 107(35.7%) 1(1%) 0.0001*** 
admin/clerical/sales 70(23.3%) 15(15%) 	  
manual labour 9(3%) 16(16%) 	  
homemaker 13(4.3%) 0(0%) 	  
unemployed 19(6.3%) 59(59%) 	  
others(students etc.) 82(27.3%) 9(9%) 	  
Type of Residence 	   	   0.0001*** 
bungalow 1(0.3%) 0(0%) 	  
semi-detached/terrace 14(4.7%) 0(0%) 	  
private 25(8%) 3(3%) 	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# Selection of metabolic syndrome (MetS) was determined by criteria set by the American 
Heart Association (AHA) & National Heart Lung and Blood Institute (NHLBI) [58]. Mila 







4/5 rooms HDB flat 186(62%) 48(48%) 	  
2/3 rooms HDB flat 53(17.7%) 30(30%) 	  
1 room HDB flat 4(1.3%) 5(5%) 	  
others 17(5.7%) 14(14%) 	  Fatty fish intake per 
week 	   	    
never 20(6%) 18 (18%) 0.0001***	  
1-2 times 136(45.3%) 46(46%) 	  
3-5 times 113(37.7%) 29(29%) 	  
6 or more 31(10%) 38(7%) 	  Daily cpz equivalents 
(mgs)  295.8(267.3) 	  
Age of Onset (years) 	   24.5(6.4)	   	  Duration of illness 





Total PANSS Score  39.7(8.8) 	  Total General 
Psychopathology Score  19.6(3.5) 	  
Total Positive 
Symptoms Score 	   10.5(4.5) 	  
Total Negative 
Symptoms Score 	   9.5(3.8) 	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6.4.2 SEM images 
Disturbances in the structural morphology of erythrocytes have been reported 
in patients with mental illnesses [221]. Normal erythrocytes are typically 
biconcave discocytes, whereas some pathologies are associated with increased 
counts of transformed erythrocytes, including cells with multiple processes, 
cells with double concavities on one side (knizocytes), and cells of dome or 
mulberry shape [221]. To reproduce the above observation, an independent 
group of blood samples from ten patients and ten controls were taken for SEM 
analysis. Demographics of these subjects were tabulated in Supplementary 
Table S4. On average, each image had close to 90 cells with 10 images 
counted per sample. When compared to controls, blood of schizophrenic 
patients showed a significant increase in intermediary forms of erythrocyte 
including an increase in numbers of cells with multiple processes, knizocytes, 
dome shapes, or mulberry shapes cells (Figure 6.1 and Supplementary Table 
S5). This was with a concomitant reduction of discocytes in schizophrenia 
patients. Mulberry-shaped cells, being the rarest form, were observed in only 3 
of the 100 images from healthy controls as compared to nearly 20 of them in 

























Figure 6.1 The morphological differences between schizophrenic patients and healthy 
controls.  
There is a significant increase in intermediary erythrocyte forms including increased numbers 
of cells with multiple processes, knizocytes, dome shapes, or mulberry shapes cells in the 
blood of schizophrenic patients as compared to healthy controls (*** p<0.05, student’s-test).  
 
6.4.3 Acceptability of analytical run (CVA)  
Similar to previous chapters, the acceptability of the run was determined by 
the average CVA of each lipid species monitored based on the QCs that were 
periodically injected across the run. The CVA of measured lipids in each batch 
ranged from 2 – 200% (Supplementary Figure S4, CVA of batch 1-10). 
Nevertheless, the average CVA of lipids in each class was mainly <10% and 
thus satisfied the FDA guideline for analytical precision acceptability [81]. 
The run-to-run analytical precision of lipids measured across the ten batches 
was also evaluated to determine the overall performance of the analytical 
platform. The run-to-run analytical precision across the ten batches was higher 
than the within-batch variation therefore indicating the presence of batch 
effect (Supplementary Figure S4, overall CVA).  
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6.4.4 Assessing of the pre-analytical precision (CVP)  
The pre-analytical precision was assessed based on the replicate erythrocyte 
samples (i.e., R samples) that were processed together with the study samples. 
The CVP of majority of the lipid species was similar to that of the CVA 
(Supplementary Figure S5). This showed that the sample processing within 
each batch was done well and with little variability. 
 
6.4.5 LOESS correction (Batch effect correction) 
Based on the CVA of each individual lipid species between the 10 batches, it 
was revealed that batch-to-batch variation was present in the dataset 
(Supplementary Figure S4, overall CVA). The CVA of each individual lipid 
species between ten batches was higher as compared to the within batch CVA 
of each individual batch. Nevertheless, batch-to-batch variation was 
successfully removed by LOESS correction (Supplementary Figure S6).  
 
6.4.6 Data filtering 
Data filtering was also performed to ensure high quality of the dataset. The 
criteria allowed only lipid species monitored to have a value of II in Chapter 5 
to be included for further analysis. As the same analytical method was applied 
for both studies, one could be certain that lipids in that list were measured with 
good analytical precision. Furthermore, only these lipids would have an index 
for providing insights to biomarker studies. Lipids used for further analysis 
were presented in Supplementary Table S1. Outliers identified in the study 
were also removed. In addition, samples in batch 10 was treated as outliers 
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and completely removed as they were found to consist of only control samples 
during un-blinding. 
 
6.4.7 Lipid analysis of the erythrocyte membrane in schizophrenic 
patients 
Morphological disorganization was observed in the erythrocyte patient 
samples that were analyzed (Figure 6.1). It is known that membrane lipids 
confer the morphology of the erythrocytes [69]. As such, lipid analysis was 
performed on the erythrocyte samples of schizophrenic patients to explore if 
they played a role in mediating the morphological abnormalities that were 
observed. A total of 158 distinct phospholipids and sphingolipids species 
previously identified and characterized for MRM screening were analyzed in 
this study. They include PA, PG, PC, PE, PS, PI, SM and GlcCer. 6 sterols 
species namely cholesterol, cholesterol ester, 24S-hydroxy-cholesterol, 22R-
hydroxycholesterol, 7-dehydrocholesterol and 27-hydroxy-cholesterol were 
also analyzed in the study (Supplementary Table S1).  
 
As shown in Figure 6.2, a subset of 27 individual lipid species were 
significantly different between the patients and controls (p<0.05). The 
majority of changes were noted in the PC, in which variable alteration was 
observed within them. Nevertheless, most of the PC species were higher in 
patients with schizophrenia as compared to the normal controls. In addition, 
the majority of significant PE lipids were down regulated in schizophrenic 
patients. Some alterations were detected in the PA, PI and PS species in which 











Figure 6.2 There were 27 lipids that were significantly altered in the erythrocyte 
membrane of schizophrenic patients. 
Group difference was evaluated using analysis of variance (ANOVA) and adjusted using 
Benjamini-Hochberg correction to control for false discovery. Bar charts represent the 
percentage (%) change over control for each significant lipid. Error bar denotes standard error 
in percentage. Out of 163 phospholipids, sphingolipids and sterols lipids, a total of 27 lipid 
species were found to be significantly different between the erythrocyte membranes of 
schizophrenic patients as compared to the healthy control. Lipids with * were significant even 




6.4.8 The II of the putative lipid signature  
As explained in Chapter 5, II provides an indicator for determining the extent 
of usefulness in assessing a single measurement of an individual’s outcome 
when compared to a population-based reference interval. A population 
reference interval is maximally sensitive when II is >1.4 and is unsuitable 
when II <0.6 [133]. In Table 6.2, the II of putative erythrocyte lipid markers 
had a median index of 0.9. Only five lipids were found to have an index of 
<0.6. The observation thus supported that majority of the elucidated lipids to 



























































































































































































Lipids with II <0.6 would indicate that their within-subject variability are 
smaller. This would also mean that these lipids have high individuality and 
thus unique to a person. As such, referencing the condition of an individual 
from a population study may not be useful. Instead, these lipids are better used 
as monitoring (state) biomarker, whereby an individual’s baseline is first 
measured and then compared to his periodical readings to determine the state 
of his condition. In contrast, lipids with II >0.6 are better used as diagnostic 
biomarkers where their reference range can be determined by levels collected 
through a population study. 
 
Through the II, it was also derived that at least 4 times of repeated 
measurement would be required for estimation of the homeostatic set point of 
the lipid signature to be within ± 15% and with 95% confidence as shown in 









Table 6.2 The index of individuality (II) of the putative erythrocyte lipid biomarker for 









CVG (%) CVI (%)  CVW (%)  CVA (%)  II             aN 
PC(731) PC(32:1) 26.8 13.8 16.5 9.0 0.6 4.6 
PC(749) PC(34:6) 22.1 7.0 12.7 10.7 0.6 2.8 
PC(759) PC(34:1) 8.7 NA 11.8 13.1 1.4 2.4 
PC(777) PC(36:6) 24.8 3.2 15.0 14.7 0.6 3.8 
PC(783) PC(36:3) 10.1 5.8 11.4 9.9 1.1 2.2 
PC(791) PC(38:6e)/PC(38:5p) 28.6 14.0 16.0 7.8 0.6 4.4 
PC(809) PC(38:4) 12.3 9.4 12.5 8.3 1.0 2.7 
PC(811) PC(38:3) 14.9 9.8 11.9 6.7 0.8 2.4 
PC(813) PC(38:2) 8.9 NA 13.6 17.7 1.5 3.2 
PC(817) PC(38:0) 22.6 19.2 20.8 8.0 0.9 7.4 
PC(819) PC(40:6e)/PC(40:5p) 19.5 17.2 18.8 7.5 1.0 6.0 
PC(835) PC(40:5) 16.0 12.8 14.6 7.1 0.9 3.6 
PC(837) PC(40:4) 13.8 11.9 13.7 6.7 1.0 3.2 
LPE(453) LPE(16:0) 21.1 18.0 20.8 10.4 1.0 7.4 
PE(717) PE(34:1) 5.8 12.9 14.5 6.8 2.5 3.6 
PE(727) PE(36:3e)/PE(36:2p) 14.0 14.2 16.5 8.3 1.2 4.6 
PE(739) PE(36:4) 6.1 11.8 13.3 6.2 2.2 3.0 
PE(747) PE(36:0) 20.2 16.3 17.4 6.2 0.9 5.2 
PE(749) PE(38:6e)/PE(38:5p) 14.0 14.0 15.9 7.5 1.1 4.3 
PE(773) PE(38:1) 22.5 15.5 17.0 6.9 0.8 4.9 
PE(775) PE(40:7e)/PE(40:6p) 15.3 12.3 14.2 7.0 0.9 3.4 
PE(777) PE(40:6e)/PE(40:5p) 6.4 12.1 13.9 6.8 2.2 3.3 
PA(696) PA(36:4) 14.9 7.4 10.3 7.2 0.7 1.8 
PA(724) PA(38:4) 8.9 10.2 11.8 5.8 1.3 2.4 
PI(836) PI(34:1) 27.4 15.9 17.2 6.7 0.6 5.1 
PI(858) PI(36:4) 24.1 16.3 17.5 6.3 0.7 5.2 
PS(809) PS(38:6) 12.8 11.0 15.1 10.3 1.2 3.9 
Median          8.1 0.9 3.4 
 
aN is the number of samples required to estimate the underlying homeostatic 
set point to be within ± 15% with 95% confidence. CVI with NA indicates the 








6.4.9 Covariant analysis 
Admittedly, sampling in this study was conducted in a natural clinical setting 
and thus not very well matched. Variability between groups in terms of 
gender, BMI, smokers, socio-economic background, diet (i.e., fatty fish 
intake) and MetS were present (Table 6.1). As a result, statistical analysis was 
performed again on the 27 lipids after adjusting for various sets of covariants. 
Out of the 27 lipids that were measured to be significantly different in 
schizophrenic patients, only three lipids were least affected by the covariants 


















Table 6.3 Covariant analysis of the 27 putative erythrocyte lipids for diagnosis of 
schizophrenia.  































PC(731) PC(32:1) 1.13967E-11 0.985158888 0.996533497 0.996408041 0.996304933 
PC(749) PC(34:6) 3.39503E-06 0.985158888 0.996533497 0.996408041 0.996304933 
PC(759) PC(34:1) 0.000166636 0.233379794 0.369210114 0.413748889 0.494886404 
PC(777) PC(36:6) 0.006653695 0.985158888 0.996533497 0.780846046 0.870366181 
PC(783) PC(36:3) 0.001721647 0.985158888 0.996533497 0.996408041 0.996304933 
PC(791) PC(38:6e)/PC(38:5p) 7.55953E-06 0.985158888 0.996533497 0.996408041 0.996304933 
PC(809) PC(38:4) 0.000116593 0.446543982 0.148281451 0.153747429 0.17416052 
PC(811) PC(38:3) 2.26013E-07 0.2196575 0.28423986 0.379724935 0.352586864 
PC(813) PC(38:2) 4.30996E-05 0.985158888 0.996533497 0.996408041 0.996304933 
PC(817) PC(38:0) 0.01823764 0.985158888 0.996533497 0.996408041 0.996304933 
PC(819) PC(40:6e)/PC(40:5p) 4.15027E-06 0.985158888 0.996533497 0.996408041 0.996304933 
PC(835) PC(40:5) 0.00610078 0.985158888 0.996533497 0.996408041 0.996304933 
PC(837) PC(40:4) 2.74131E-05 0.985158888 0.996533497 0.996408041 0.996304933 
LPE(453) LPE(16:0) 0.004390111 0.985158888 0.996533497 0.996408041 0.996304933 
PE(717)* PE(34:1)* 0.986765544 0.008233957 0.019505739 0.032915995 0.008088146 
PE(727) PE(36:3e)/PE(36:2p) 3.36532E-05 0.985158888 0.996533497 0.996408041 0.996304933 
PE(739)* PE(36:4)* 1.89253E-05 0.046617873 0.061812056 0.084433115 0.048538439 
PE(747) PE(36:0) 0.000400859 0.985158888 0.996533497 0.996408041 0.996304933 
PE(749) PE(38:6e)/PE(38:5p) 3.63867E-06 0.985158888 0.996533497 0.996408041 0.996304933 
PE(773) PE(38:1) 0.000250949 0.985158888 0.996533497 0.996408041 0.996304933 
PE(775) PE(40:7e)/PE(40:6p) 0.004259305 0.985158888 0.996533497 0.996408041 0.996304933 
PE(777) PE(40:6e)/PE(40:5p) 0.000209065 0.985158888 0.996533497 0.996408041 0.996304933 
PA(696) PA(36:4) 0.02309656 0.985158888 0.996533497 0.996408041 0.996304933 
PA(724) PA(38:4) 5.04281E-06 0.985158888 0.996533497 0.996408041 0.996304933 
PI(836) PI(34:1) 0.04516851 0.985158888 0.996533497 0.996408041 0.996304933 
PI(858) PI(36:4) 8.6513E-05 0.985158888 0.996533497 0.996408041 0.996304933 
PS(809)* PS(38:6)* 0.012966637 0.350023523 0.058585911 0.039053268 0.034690822 
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6.4.10 Development of diagnostic classifier 
To ensure that the putative lipid signature was not biased towards 
confounders, only the three lipids that were least affected by the covariants 
were analyzed for their diagnostic ability using linear discriminant analysis. 
The output of linear discriminant analysis was visualized in a 2 × 2 matrix 
(Figure 6.3). It was found that 65 of 99 case samples were correctly predicted 
as schizophrenic patients (65.7% specificity), and 167 of 252 (66.3% 
specificity) control samples were correctly categorized as controls with an 
overall accuracy of 66.1% (Figure 6.6 (A)). A leave-one-out cross-validation 
was performed to test the reliability of the model. The cross-validation set 
showed a sensitivity of 62.6% and a specificity of 65.9%, with an overall 









Figure 6.3 Diagnostic model in a clinical perspective.  
A) Linear discriminant analysis. The sensitivity and specificity of the model were 65.7% and 
66.3% respectively. The positive predictive value (PPV) and negative predictive value (NPV) 
were 43.3% and 83.1%, with an accuracy of 66.1%. B) Leave-one-out cross-validation. The 
sensitivity and specificity of the model were 62.6% and 65.9% respectively. The PPV and 























































6.5.1 Aim and rationale  
Schizophrenia is known to be a highly severe and impairing mental disorder 
[234] that causes large social-economic impacts on the patients [235]. 
Regrettably, even with decades’ worth of research, there is currently no 
biologically validated tool for the diagnosis of schizophrenia. The 
conventional method to diagnose and assess the condition of this mental 
disorder is purely based on subjective clinical interviews [60]. The etiology of 
schizophrenia is no doubt complex but research over the years has 
accumulated strong evidence of Horrobin’s postulation of a membrane 
phospholipid deficit in the brain of schizophrenic patients [213]. Interestingly, 
aberrations of the membrane phospholipids is also observed in peripheral 
blood cells such as the erythrocytes [52]. It is known that lipids play a role in 
determining the morphology of erythrocytes. The possibility of membrane 
lipid deficits was also highlighted in a morphological study of the 
erythrocytes, where a higher proportion of structurally abnormal erythrocytes 
was found in schizophrenic patients as compared to healthy individuals [221].  
 
Erythrocytes are easily accessible and thus a less invasive source of diagnostic 
sample than the brain [236]. Furthermore, with the support of strong analogy 
between the erythrocytes and the neuronal membrane [218-220], the study 
thus sets forth to determine if a potential lipid signature could be elucidated 
from the erythrocyte membrane to aid in the diagnosis of schizophrenia.   
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6.5.2 Elucidation of a putative lipid-based signature from the 
erythrocyte membrane for the diagnosis of schizophrenia  
Disturbances in the structural morphology of erythrocytes have been reported 
in patients with mental illnesses [221]. These changes are believed to result 
from alterations in the biological properties of cells, especially in membrane 
fluidity and ion transport [229, 237, 238]. In this study, a high number of 
morphological abnormalities were found in the erythrocyte membrane of 
schizophrenic patient samples and were in accordance with previous 
observation [221]. Since lipids regulate the shape of the erythrocytes, profiling 
of the erythrocyte membrane that comprises 164 lipids was thus done. A 
subset of 27 lipids was found to be significantly different between the patients 
and the controls even after controlling for false discoveries. The majority of 
these lipids were of PCs and PEs, which are major classes of the erythrocyte 
membrane [68]. Even though cholesterol is also a chief component of the 
erythrocyte membrane, they were not significantly altered between the 
schizophrenic patients and controls. This also holds true for the sterol 
derivatives. 
 
6.5.2.1 Elucidated erythrocyte lipid signature was in accordance with the 
literature 
The most notable observation of this study was that most PEs was down 
regulated in schizophrenic patients. This was with strong concordance to 
existing literature (Table 6.4) where different investigators separately reported 
a consistent decrease in the erythrocyte membrane PE in both medicated and 
drug free patients [213, 229, 239-241]. Furthermore, previous work has shown 
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both an increase in SM and a decrease of PC in the erythrocyte membranes of 
schizophrenic patients whereas no apparent differences were observed in the 
levels of other phospholipids [213, 229, 239-241]. However, this is in striking 
contrast with the present study. Instead, no SM was found to be different. In 
addition, variable alteration was found in the PC of schizophrenic patients. 
These differences in observation could be highly attributed to the varying 
types of techniques being utilized. To begin with, previous investigations of 
the erythrocyte lipidome that specifically monitored the phospholipids and 
sphingolipids in schizophrenic patients are scarce. Moreover, due to the 
limited availability of technologies in the past, low-resolution TLC was the 
primary method for lipid separation. Visualization of the separated lipids was 
done by staining of unsaturated fatty acids using iodine vapour [213]. 
Consequently, the complete spectrum of differences between the lipid classes 
may not have been displayed. Furthermore, the strength and reliability of 
previous studies may have been undermined as the sample sizes used were of 
smaller numbers of schizophrenic patients (ranging from 13 to 54 patients) 
[213, 229, 239-241]. 
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Table 6.4 Summary of erythrocyte membrane studies examining phospholipids in 
schizophrenic patients. 
 
Nevertheless, observations of the current lipid signature elucidated in this 
study were supported in other ways. Firstly, out of the 27 significant lipid 
species, six ether PC and PE lipids were reduced in schizophrenic patients. 
This was similar to a recent study by Kaddurah-Daouk et al. [235], where a 
reduction of ether PCs and ether PEs (specifically the plasmalogens) were 
measured between never medicated and chronic relapsing patients as 
compared to the controls. The reduction in ether lipids appeared even at the 
onset of the disorder in drug naïve patients and is therefore believed to be a 
trait of schizophrenia and not due to influence of treatment [235]. Admittedly, 
PC and PE plasmalogen abnormalities were monitored in the plasma and not 
the erythrocyte membrane of schizophrenic patients; future studies need to be 
conducted to validate the observation. Nevertheless, both findings support that 
schizophrenia is strongly associated with reduction of blood ether lipids and 
Study Methodology Sample Drug Treatment Phospholipids 
        PS PE PC PI SM 
1982 Lautin, A. et al TLC 54 SCZ Yes;           
  HPLC 41 controls  Various types & doses   
          
1984 Hitzemann, R. et al TLC 38 SCZ Drug free for 2 weeks ↓   
    14 SF     
    15 manic patients     
    35 controls     
          
1993 Keshavan M. S. et al High performance TLC 13 SCZ 
Drug free for at least 1 
month ↓ ↑ 
  
Scanning laser 
densitometry 11 controls     
          
2001 Ponizovsky A. M. et al TLC 32 SCZ Yes;  ↓ ↑ 
    (13 positive symptom;  Haloperidol   
    19 negative symptom)     
    14 controls     
          
2002 Ryazantseva N. V. et al TLC 18 paranoid SCZ Yes; ↓ ↓   
  Flurochrome Assay 
24 mental retardation 
patients Various types & dose   
    
24 neurotic disorders 
patients     
    45 controls     
                  
Schizophrenic patients (SCZ); Schizophrenic form disorder patients (SF) 
Thin layer chromatography (TLC); High performance liquid chromatography (HPLC); Liquid chromatography (LC) 
Phosphatidylserine (PS), Phosphatidylethanolamine (PE),  Phosphatidylcholine (PC), Phosphatidylinositol (PI) and Sphingomyelin (SM) 
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that blood ether lipids may be potential biomarkers for the diagnosis of this 
mental disorder [235].  
 
Furthermore, PUFA modification of the erythrocyte membrane in 
schizophrenic patients was also observed in this study. It was found that, other 
than the ether PC and ether PE lipids, there were some diacyl PC (i.e., PC 
34:6, PC 36:6) and PS species (i.e., PS 38:6) attached to PUFA that were 
reduced in the erythrocytes of patients. Indeed, a considerable number of 
findings have shown marked reduction of PUFA in the erythrocyte membrane 
of schizophrenic patients [242-244]. This was also highlighted in a recent 
systematic meta-analysis of erythrocyte membrane PUFA alteration in 
schizophrenia [234]. A total of 18 studies focusing on four main PUFA, 
namely docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), LA and 
AA, were examined. Even so, anti-psychotics are known to be able to increase 
both peripheral and central PUFA levels through the up-regulation of 
biosynthetic enzyme expression and activation [234, 245]. After careful 
considerations of the use of anti-psychotics, it was found that depletion in 
PUFA, such as DPA, DHA and in particular AA, was strongly associated with 
the symptomology of schizophrenia [234]. 
 
6.5.2.2 Reduction in ether lipids and PUFA maybe a result of oxidative 
stress in schizophrenic patients 
Taken together, observation of reduction in both ether lipids and PUFA has 
been reported in not just the erythrocytes but also in brain homogenates of 
schizophrenic patients [229, 246]. There is thus strong reason to believe that 
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both of these lipids have a strong biological role in schizophrenia. Currently, 
large body of support has found oxidative stress to be involved in the 
pathophysiology of schizophrenia [247]. This includes indirect measures of 
free radical activities through markers such as superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase [247-250], and direct measures of 
oxidative damage [251, 252] in schizophrenic patients. Interestingly, several 
lines of evidence have pointed lipids to decrease oxidative stress [235, 250]. In 
particular, ether lipids are known to serve as endogenous antioxidants [253]. 
As shown in Figure 6.7, it is a well-known phenomenon that in both the blood 
and brain of schizophrenic patients, PLA2 is elevated [179, 214, 215]. PLA2 is 
a metabolic enzyme of the membrane that causes the release of AA from 
membrane phospholipids and TG [250, 254]. The release of AA is 
subsequently metabolized by cyclooxygenase and leads to the synthesis of 
prostaglandins [254]. Synthesis of prostaglandin is one of the factors which 
involves the formation of free radicals and causes the successive continuation 
of lipid peroxidation [250]. Due to the structure of the ether lipids and PUFA, 
they are more prone to attacks by the increase in reactive oxygen species 
(ROS) than saturated fatty acids and cholesterol. As a consequence, it is no 





















Figure 6.4 Schematic diagram representing the process of oxidative stress, which leads to 
reduction in polyunsaturated fatty acids (PUFA) and ether lipids.  
Elevated phospholipase A2 (PLA2) causes the release of arachidonic acid (AA) from 
membrane phospholipids and triacylglycerides. The release of AA is subsequently 
metabolized by cyclooxygenase (COX1/2) leading to the synthesis of prostaglandins (PGH2). 
The synthesis of PGH2 involves the formation of free radicals and successive continuous of 
lipid peroxidation on PUFA and ether species. O2·- superoxide; SOD, superoxide dismutase; 
CAT, catalase; H2O2 hydrogen peroxide; GSH-Px, glutathione peroxidase; GSH, reduced 
glutathione; GSSG, oxidized glutathione; GSH-Red, glutathione reductase; ·OH, hydroxyl 
radical (the most potent free oxygen radical). Modified from Herken et al. 2001, Emanuela 
and FitzGerald 2011 [250, 254].  
 
6.5.3 Application of II to putative lipid signature 
This is the first study that incorporates and applies information on BV to 
biomarker studies. Undeniably, valuable information can be derived from it. 
As mentioned in Chapter 5, knowledge of BV can be used in designing the 
appropriate biomarker experiment (i.e., population study), requesting for the 
correct samples (i.e., single or serial sampling) and possibly helping in the 
interpretation of the data [133]. 
 
It has already been shown in Chapter 5 that a population-based study is 
generally suitable for the erythrocyte lipidome as the II of most erythrocyte 




taken such that lipid signature from the erythrocytes could be elucidated and 
used in the diagnosis of schizophrenia. Through this study, it was identified 
that the II of majority of the putative lipid signature were mainly >0.6 and thus 
emphasized the validity of the elucidated marker derived from a population-
based study. 
 
In addition, valuable insights were also revealed from the II. Based on the 
index of each elucidated lipid marker, one is able to make a quick judgment if 
a lipid is better used as a monitoring (state) or diagnostic (trait) marker. 
Typically, lipids with II <0.6, are known to have a smaller within-subject 
variation. This will suggest that these lipids have high individuality and are 
thus extremely unique in each individual. As a consequence, determining the 
condition of a disease based on a population reference may provide one with 
the wrong results. Instead, these lipids should be utilized as monitoring 
biomarkers through regular measurement in an individual to determine the 
state of a disease condition. On the other hand, lipids with II >0.6 can act as 
diagnostic biomarkers. Even though the within-subject variability of the lipids 
is high, their between-subject variability is lower. As a result, a population-
based study will collect very good reference intervals of patients and controls 
that can then be used in the diagnosis of the disease.  
 
Furthermore, information on the sampling number needed in a study can also 
be obtained from the II. Regardless of a high or low II, it is vital to have an 
impression of the number of samples required in estimating the underlying 
homeostatic set point in a person. In usual clinical or laboratory practice, only 
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a single sample is taken from an individual. However, this may not be 
sufficient as intrinsic analytical and within-subject variation can influence 
each result. As a consequence, the reliability of the lipid signature may be 
compromised and thus not produce valid results. Irrefutably, this information 
is always missing in biomarker studies. However, this is the first study that 
delivers this piece of knowledge. The knowledge is highly crucial for planning 
of future validation studies or even execution in clinical setting. 
 
6.5.4 Possibilities of confounding effect on the lipid signature 
The recruited participants of the study well represent the natural clinical 
setting in many ways. However, a number of covariants may have a strong 
influence on the elucidated lipid signature. This includes factors such as 
gender disproportion, smoking status, MetS and the use of anti-psychotics, 
which are all known to be characteristics in schizophrenia.  
 
6.5.4.1 Gender and smoking 
In this study, a higher proportion of males were being diagnosed with 
schizophrenia. This highlights a well-described phenomenon where males 
have a greater incidence of developing schizophrenia as compared to females 
(Incidence Risk Ratio of Male: Female = 1.42) [255, 256]. Though this well 
mimics real life, it is apparent that the smaller number of females recruited in 
the schizophrenia patients may lead to generalization of the findings. 
Likewise, the current study recruited a higher number of smokers in 
schizophrenic patients than the controls. This observation is also characteristic 
of schizophrenia where the reported prevalence of smoking is significantly 
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higher in patients (60-90%) and lower in the controls (23-30%) [257]. 
Moreover, the number of cigarettes smoked by the patients is more than that 
of the controls [257]. To complicate matters, the effect of smoking is known to 
influence lipids. In particular, cigarette smoke is highly pro-oxidant [258] and 
can therefore potentially cause the aberration in plasmalogens and PUFA of 
the erythrocytes [235, 259]. However, this postulation is still inconclusive as 
the evidence is mixed [260-262].  
 
6.5.4.2 Anti-psychotics and MetS 
In the case of anti-psychotics, evidence has pointed that the use of these drugs 
may be implicated in lipid metabolism. It has been shown that atypical anti-
psychotics significantly increase the AA and DHA levels in erythrocyte 
membrane of schizophrenic patients [263-265]. Furthermore, in vivo 
experiments deciphering the biosynthesis of lipids under the influence of 
various anti-psychotics have found reduction in cholesterol synthesis with a 
concomitant increase in production of TG, phospholipids and fatty acids in 
primary hepatocyte cultures exposed to these drugs [266-268]. However, there 
were no signs of cholesterol reduction found in this study. Furthermore, 
reductions in plasmalogens and PUFA have also been well supported in drug 
naïve individuals [235, 269-271]. Nevertheless, as the recruited patients in the 
current study were chronic users of anti-psychotic drugs, one cannot rule out 
that the observed erythrocyte membrane deficit in the current study may be an 
effect of treatment.  
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Major concern regarding treatment of schizophrenia using anti-psychotics has 
also been implicated in the development of MetS [272]. MetS is a condition 
that is recognized as a risk factor of cardiovascular morbidity and mortality 
[273]. The criteria of MetS include elevated TG, blood pressure, fasting 
glucose, abdominal obesity, and a reduction in HDL [231]. An individual is 
characterized to suffer from MetS if he fulfills three of the criteria. In this 
study, MetS was examined between the patients and controls. A higher 
proportion of schizophrenic patients were found to have MetS as compared to 
the controls. Through this observation, one can infer that individuals with 
MetS have higher body weight and signs of dyslipidemia, which are all 
indications of anti-psychotic side effects [266]. Indeed, a meta-analysis [272] 
of published literature on MetS in schizophrenia has highlighted the 
prevalence of MetS to range from 4.7% - 68% in drug treated patients. In 
contrast, MetS ranges from 3.3% - 26% in drug naïve schizophrenic patients. 
More importantly, as a large proportion of patients in this study have MetS 
and are drug treated, there is a high possibility that a drug associated lipid 
dysregulation is present in them, which may have influence on the elucidated 
erythrocyte lipid signature.  
 
Taken together, the potential influence of each factor is recognized in the 
current study. Evidently, the design of the current study is cross-sectional. As 
such, further investigations using longitudinal studies would be required in 
order to decipher the causation of smoking, anti-psychotics and MetS with 
regards to their association with the putative lipid signature elucidated from 
the erythrocyte membrane of schizophrenic patients. 
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6.5.5 Development of a diagnostic classifier for schizophrenia 
Multiple confounders were present in this study. In order to ensure that the 
bias contributed by the covariants did not implicate the putative signature, 
only lipids that were still statistically significant after adjusting for various 
covariants were used in the classifier. In this study, 27 lipids were identified to 
be significantly different in the erythrocyte membrane of schizophrenic 
patients. However, only three lipids were least affected by the covariants. 
Nonetheless, an adjunct tool for the diagnosis of schizophrenia was tested 
using the three lipids. The discriminant indices generated by the putative lipid 
signature provided a modest accuracy of 66.1%, with specificity and 
sensitivity of 65.7% and 66.3% respectively. The specificity of the classifier 
implied that two-thirds of the healthy individuals were correctly tested 
negative for schizophrenia. A NPV of 83.1% indicated a high likelihood that 
an individual does not have schizophrenia when tested negative. Similarly, the 
sensitivity of the test showed that two-thirds of individuals with schizophrenia 
were identified as cases by the putative biomarker, while the other one-third 
with schizophrenia was missed. Regrettably, the current elucidated lipid 
marker may not be sensitive enough in identification of schizophrenia as the 
PPV showed that only 43% of those tested positive would indeed have the 
mental disorder.  
 
Admittedly, the current lipid classifier exhibited only a modest ability to 
identify schizophrenic patients from the healthy control. However, adjunct 
structural clinical interviews or even other forms of biomarker can be used in 
combination to achieve a higher accuracy in identifying the true schizophrenic 
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patients. Nevertheless, the current classifier is considerably unbiased as it is 
composed of lipids that were thoroughly tested for covariant effects. By only 
employing the few lipids that were least affected by the confounders, this 
study has elucidated a reasonable classifier that is not over fitted.  
 
6.5.6 Strengths 
There are numerous strengths in this study. Firstly, the collection of samples 
was done in a single site to avoid sampling bias. Moreover, the same team of 
personnel was involved in the collection of samples to circumvent variability. 
Furthermore, this is one of the few biomarker studies that evaluated the 
precision of pre-analytical (only sample processing) and analytical variation to 
ensure that the putative lipid signature was not elucidated due to technical 
variation. In addition, this is one of the first biomarker studies where 
knowledge of BV was brought in to provide valuable insights needed for 
biomarker discovery. Through the list of II in Chapter 5, information on the 
estimated number of required samples can be determined to allow for accurate 
reading. Moreover, the II can also allow suggestion as to which lipids are 
more suitable as a diagnostic (trait) or monitoring (state) biomarker. The 
current study has a relatively large sample size where identification of a 
comprehensive coverage of erythrocyte lipids was conducted in a sensitive 
and specific targeted approach, making it more superior than other 
investigations. Thorough demographics were also collected for this study such 
that confounders that strongly influenced the putative lipid signature were 
identified. This is of great use as association studies of various confounders 
could be done in future to truly determine their relationship with the lipid 
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signature. Finally, demonstration of a relatively unbiased lipid classifier was 
also generated through this study.  
 
6.5.7 Limitations 
The current identified lipids are only putative biomarkers and should not be 
interpreted as a diagnostic tool for schizophrenia. It is undeniable that 
treatment intervention of drugs can be of great influence to the lipid signature. 
A major drawback of the study is such that the recruited schizophrenic 
patients were not drug naïve but mainly chronic users of anti-psychotic drugs. 
Being a cross-sectional study, information regarding causation of drugs could 
not be derived. As such, longitudinal studies should be conducted in future to 
establish the effects of drugs on the lipid signature. Furthermore, confounding 
factors such as diet, socio-economic status, smoking, MetS and specificity 
towards other psychotic disorders had not been thoroughly examined for. 
Nevertheless, the study has provided hints in area that requires additional 
detailed analysis to determine if these factors do indeed have an influence on 
the lipid signature. Furthermore, validation tests in larger independent samples 
by independent laboratory and personnel have yet been done.  
 
6.5.8 Conclusion 
Biomarker efforts have been demonstrated in many areas of research. 
However, it is still a challenge to identify a reliable signature, which could aid 
or even replace current methods of diagnosis in schizophrenia. This is 
currently the most comprehensive lipid analysis of the erythrocyte membrane 
of schizophrenic patients and healthy controls. Demonstration of the potential 
 126 
use of the identified lipid signature elucidated from the erythrocyte membrane 
was also done in the study. To ensure that the reliability of the identified lipid 
signature is of a metabolic end point, technical variation was assessed and was 
determined to be low. More importantly, this is the first study to apply 
knowledge of BV in biomarker development and has provided additional 
insights required in planning of future validation study. 
 
The putative lipid signature is well supported to have biological association 
with schizophrenia. Efforts in covariant analysis have generated a relatively 
unbiased classifier in this study. However, its ability to discriminate between 
patients and controls was only modest. Nevertheless, it may still be useful in 
the diagnosis of schizophrenia if used concurrently with current diagnostic 
methods or even other biomarkers. More importantly, this study has formed a 
strong basis for ongoing biomarker research. With continuous efforts of 
understanding common confounders and implementing rigorous testing of 
putative markers, we should be one step closer to identifying a strong 




7. Final Conclusion 
 
Taken together, this thesis has employed a targeted mass spectrometry 
approach to study a comprehensive coverage of the erythrocyte lipidome.  
This includes the phospholipids, sphingolipids and sterols, which are major 
components of the erythrocyte membrane. Strong emphasis has been put into 
measurement of pre-analytical and analytical precision in the entire thesis to 
ensure that all findings have a biological meaning and are not due to technical 
variation. 
 
Considerable effort has also been made in characterizing the BV in the 
erythrocyte lipidome, which has important implications in biomarker 
development. Firstly, investigation between fasting and non-fasting blood in 
the erythrocyte lipidome has uncovered no added advantage of using fasting 
blood when studying the erythrocyte lipidome. In fact, a non-fasting blood 
sample is more representative of the usual metabolic state in our body. 
Furthermore, this would also mean the convenience of utilizing a biomarker 
elucidated from the erythrocyte lipidome as the compliance of overnight fast is 
not needed.  
 
More importantly, the study of BV focused on between- and within-subjects 
variations in the erythrocyte lipidome has revealed much valuable information 
that has undeniably strong implications in biomarker discovery. Through this 
study, an important gap in the understanding of BV in the erythrocyte 
lipidome has been filled. Apart from which, an approach of evaluating natural 
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BV in the context of lipid analytes using II has also been demonstrated. This 
approach is novel in the field of lipidomics and has great benefits in 
biomarkers development. In this thesis, elucidation of a diagnostic lipid 
signature of schizophrenia has been used as a platform to showcase the value 
of the II. The II has shown to be able to evaluate if a population-based study is 
useful in yielding relevant signature biomarker. Moreover, suitability of a lipid 
as a monitoring (state) or diagnostic (trait) biomarker could also be determined 
by the II. Finally, an estimate of the required number of samples to properly 
















8. Future Perspectives 
 
Important areas that need to be investigated to further our knowledge of BV 
and biomarker development in the erythrocyte lipidome are discussed below.  
 
8.1 BV in the erythrocyte lipidome 
This thesis has revealed a framework to characterize BV in the erythrocyte 
lipidome. Furthermore, a novel approach through utilization of the II in 
lipidomics has been demonstrated and serves to be extremely valuable in 
biomarker development. Admittedly, the current study is of a limited sample 
size and stratified to male Chinese aged between 31-39 with emphasis on 
phospholipids, sphingolipids and sterols of the erythrocyte membrane. Thus, 
similar work in a larger population looking at different lipid species, gender, 
ethnicity and also age group need to be conducted in future to have a complete 
picture of BV in the erythrocyte lipidome. Nonetheless, demonstration of the 
use of II in this study has proven to be highly beneficial. As this work is novel 
in the field of lipidomics, future work extending to other biological fluids 
should also be done. In addition, the information should be collected into a 
database and then shared with any investigators interested in lipidomics 
biomarker discovery.  
 
8.2 Biomarker development in the diagnosis of schizophrenia 
The framework of biomarker discovery in this thesis is well established and a 
relatively unbiased putative lipid signature for the diagnosis of schizophrenia 
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was elucidated. However, a major shortcoming in the study was the presence 
of numerous confounders that had strong effects on the lipid signature. 
Evidently, future studies should be undertaken to truly understand the 
association of various confounders with the elucidated lipid signature. Only 
through longitudinal studies would the causative effect of each association be 
understood. With such information, stronger and more reliable lipid 
biomarkers of schizophrenia could then be selected. Furthermore, emphasis on 
rigorous testing using independent cohorts and an independent group of 
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Supplementary Table S1 Multiple reaction monitoring (MRM) transitions of the 
erythrocyte membrane lipids used in this thesis.  
 
Phospholipids and Sphingolipids 
(x - indicates that the lipid was measured in the particular chapter) 
 
Mode MRM Class 










positive 552.5/184.1 Lyso PC STD LPC(551) STD LPC(20:0) x x 
positive 496.5/184.1 Lyso PC LPC(495) LPC(16:0) x   
positive 510.5/184.1 Lyso PC LPC(509) LPC(18:0e) x   
positive 520.5/184.1 Lyso PC LPC(519) LPC(18:2) x   
positive 522.5/184.1 Lyso PC LPC(521) LPC(18:1) x   
positive 524.5/184.1 Lyso PC LPC(523) LPC(18:0) x   
positive 544.5/184.1 Lyso PC LPC(543) LPC(20:4)     
positive 546.5/184.1 Lyso PC LPC(545) LPC(20:3) x   
positive 678.6/184.1 PC STD PC(677) STD PC(28:0) x x 
positive 706.7/184.1 PC PC(705) PC(30:0)   x 
positive 718.7/184.1 PC PC(717) PC(32:1e)/PC(32:0p) x x 
positive 720.7/184.1 PC PC(719) PC(32:0e)/PC(32:1p) x x 
positive 730.7/184.1 PC PC(729) PC(32:2)   x 
positive 732.7/184.1 PC PC(731) PC(32:1)   x 
positive 734.7/184.1 PC PC(733) PC(32:0)   x 
positive 738.7/184.1 PC PC(737) PC(34:4p) x x 
positive 742.7/184.1 PC PC(741) PC(34:3e)/PC(34:2p) x x 
positive 744.7/184.1 PC PC(743) PC(34:2e)/PC(34:1p)   x 
positive 746.7/184.1 PC PC(745) PC(34:1e)/PC(34:0p)   x 
positive 748.7/184.1 PC PC(747) PC(34:0e)   x 
positive 750.7/184.1 PC PC(749) PC(34:6) x x 
positive 754.7/184.1 PC PC(753) PC(34:4) x x 
positive 756.7/184.1 PC PC(755) PC(34:3)   x 
positive 758.7/184.1 PC PC(757) PC(34:2)   x 
positive 760.7/184.1 PC PC(759) PC(34:1)   x 
positive 762.7/184.1 PC PC(761) PC(34:0)   x 
positive 766.7/184.1 PC PC(765) PC(36:5e)/PC(36:4p) x x 
positive 768.7/184.1 PC PC(767) PC(36:4e)/PC(36:3p) x x 
positive 770.7/184.1 PC PC(769) PC(36:3e)/PC(36:2p) x x 
positive 772.7/184.1 PC PC(771) PC(36:2e)/PC(36:1p) x x 
positive 774.7/184.1 PC PC(773) PC(36:1e)/PC(36:0p)   x 
positive 776.7/184.1 PC PC(775) PC(36:0e)     
positive 778.7/184.1 PC PC(777) PC(36:6) x x 
positive 780.8/184.1 PC PC(779) PC(36:5) x x 
positive 782.8/184.1 PC PC(781) PC(36:4) x x 
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positive 784.8/184.1 PC PC(783) PC(36:3) x x 
positive 786.8/184.1 PC PC(785) PC(36:2)   x 
positive 788.8/184.1 PC PC(787) PC(36:1) x x 
positive 790.8/184.1 PC PC(789) PC(36:0) x x 
positive 792.6/184.1 PC PC(791) PC(38:6e)/PC(38:5p) x x 
positive 794.6/184.1 PC PC(793) PC(38:5e)/PC(38:4p) x x 
positive 796.6/184.1 PC PC(795) PC(38:4e)/PC(38:3p) x x 
positive 798.6/184.1 PC PC(797) PC(38:3e)/PC(38:2p) x x 
positive 800.8/184.1 PC PC(799)  PC(38:2e)/PC(38:1p)  x x 
positive 802.8/184.1 PC PC(801) PC(38:1e)/PC(38:0p) x x 
positive 804.8/184.1 PC PC(803) PC(38:7) x x 
positive 806.8/184.1 PC PC(805) PC(38:6) x x 
positive 808.8/184.1 PC PC(807) PC(38:5) x x 
positive 810.8/184.1 PC PC(809) PC(38:4) x x 
positive 812.8/184.1 PC PC(811) PC(38:3) x x 
positive 814.8/184.1 PC PC(813) PC(38:2) x x 
positive 816.8/184.1 PC PC(815) PC(38:1)     
positive 818.8/184.1 PC PC(817) PC(38:0) x x 
positive 820.8/184.1 PC PC(819) PC(40:6e)/PC(40:5p) x x 
positive 822.8/184.1 PC PC(821) PC(40:5e)/PC(40:4p) x x 
positive 824.8/184.1 PC PC(823) PC(40:4e)/PC(40:3p) x x 
positive 826.8/184.1 PC PC(825) PC(40:3e)/PC(40:2p)   x 
positive 828.8/184.1 PC PC(827) PC(40:2e)/PC(40:1p)   x 
positive 830.8/184.1 PC PC(829) PC(40:8) x x 
positive 832.8/184.1 PC PC(831) PC(40:7) x x 
positive 834.8/184.1 PC PC(833) PC(40:6) x x 
positive 836.6/184.1 PC PC(835) PC(40:5) x x 
positive 838.8/184.1 PC PC(837) PC(40:4) x x 
positive 862.8/184.1 PC PC(861) PC(42:6)   x 
positive 892.8/184/1 PC PC(891) PC(44:5) x   
positive 647.6/184.4 SM STD SM(646) STD SM(d18:1/12:0) x x 
positive 675.6/184.1 SM SM(674) SM(32:1) x x 
positive 689.9/184.1 SM SM(688) SM(33:1) x x 
positive 691/7/184.1 SM SM(690) SM(33:0) x x 
positive 701.7/184.1 SM SM(700) SM(34:2) x x 
positive 703.7/184.1 SM SM(702) SM(34:1) x x 
positive 705.7/184.1 SM SM(704) SM(34:0) x x 
positive 727.8/184.1 SM SM(726) SM(36:3) x x 
positive 729.8/184.1 SM SM(728) SM(36:2) x x 
positive 731.8/184.1 SM SM(730) SM(36:1) x x 
positive 733.8/184.1 SM SM(732) SM(36:0) x x 
positive 757.7/184.1 SM SM(756) SM(38:2) x x 
positive 759.7/184.1 SM SM(758) SM(38:1) x x 
positive 785.8/184.1 SM SM(784) SM(40:2) x x 
positive 787.8/184.1 SM SM(786) SM(40:1) x x 
positive 789.9/184.4  SM SM(788) SM(40:0) x x 
positive 799.8/184.1 SM SM(798) SM(41:2) x x 
positive 801.1/184.1 SM SM(801) SM(41:1) x x 
positive 813.9/184.1 SM SM(812) SM(42:2) x x 
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positive 815.9/184.1 SM SM(814) SM(42:1) x x 
positive 817.9/184.4 SM SM(816) SM(42:0) x x 
positive 827.8/184.1 SM SM(826) SM(43:2) x x 
positive 829.8/184.1 SM SM(828) SM(43:1) x x 
positive 831.8/184.1 SM SM(830) SM(43:0) x x 
positive 839.9/184.1 SM SM(838) SM(44:3) x x 
positive 841.9/184.4 SM SM(840) SM(44:2) x x 
positive 843.9/184.4 SM SM(842) SM(44:1) x x 
positive 873.8/184.1 SM SM(872) SM(46:0) x   
positive 552.7/264.4 Cer STD Cer(551) STD Cer(d18:1/17:0) x x 
positive 538.7/264.4 Cer Cer(537)   Cer(34:1)   x   
positive 566.7/264.4 Cer Cer(565)  Cer(36:1)  x   
positive 594.7/264.4 Cer Cer(593)   Cer(38:1)   x   
positive 622.8/264.4 Cer Cer(621)  Cer(40:1)  x   
positive 638.7/264.4 Cer Cer(637) Cer(d16:1/24:0) x   
positive 648.9/264.4 Cer Cer(647)   Cer(d18:1/24:1)   x   
positive 650.9/266.4   Cer Cer(649)   Cer(d18:0/24:1)   x   
positive 652.9/266.4 Cer Cer(651) Cer(d18:0/24:0) x   
positive 588.8/264.4 GluCer STD GlcCer(587) STD GluCer(d18:1/8:0) x x 
positive 700.7/264.4  GluCer MonoHexCer(696) MonoHexCer(d18:1/16:0) x   
positive 728.7/264.4  GluCer MonoHexCer(727)   MonoHexCer(d18:1/18:0)   x   
positive 756.7/264.4   GluCer MonoHexCer(755)   MonoHexCer(d18:1/20:0)   x x 
positive 784.8/264.4 GluCer MonoHexCer(783)   MonoHexCer(d18:1/22:0)   x x 
positive 810.9/264.4 GluCer MonoHexCer(809)   MonoHexCer(d18:1/24:1)   x x 
positive 812.9/264.4  GluCer MonoHexCer(811)   MonoHexCer(d18:1/24:0)   x x 
positive 946.7/264.3 GluCer DHCer(945) DHCer(d18:1/22:0) x   
negative 424.5/196.1 LysoPE STD LPE(425) STD LPE(14:0) x x 
negative 436.5/196.1 LysoPE LPE(437) LPE(16:0p)/LPE(16:1e) x x 
negative 450.5/196.1 LysoPE LPE(451) LPE(16:1)     
negative 452.5/196.1 LysoPE LPE(453) LPE(16:0) x x 
negative 462.5/196.1 LysoPE LPE(463) LPE(18:1p)/LPE(18:2e)   x 
negative 464.5/196.1 LysoPE LPE(465) LPE(18:0p)/LPE18:1e) x x 
negative 476.5/196.1 LysoPE LPE(477) LPE(18:2) x x 
negative 478.5/196.1 LysoPE LPE(479) LPE(18:1) x x 
negative 480.5/196.1 LysoPE LPE(481) LPE(18:0) x x 
negative 500.5/196.1 LysoPE LPE(501) LPE(20:4) x   
negative 634.6/196.1 PE STD PE(635) STD PE(14:0/14:0) x x 
negative 686.7/196.1 PE PE(687) PE(32:2)     
negative 700.7/196.1 PE PE(701) PE(34:2e)/PE(34:1p) x x 
negative 714.7/196.1 PE PE(715) PE(34:2) x x 
negative 716.7/196.1 PE PE(717) PE(34:1) x x 
negative 722.7/196.1 PE PE(723) PE(36:4p) x x 
negative 724.7/196.1 PE PE(725) PE(36:4e)/PE(36:3p) x x 
negative 726.7/196.1 PE PE(727) PE(36:3e)/PE(36:2p) x x 
negative 728.7/196.1 PE PE(729) PE(36:2e)/PE(36:1p) x x 
negative 738.7/196.1 PE PE(739) PE(36:4) x x 
negative 740.7/196.1 PE PE(741) PE(36:3) x x 
negative 742.7/196.1 PE PE(743) PE(36:2) x x 
negative 744.8/196.1 PE PE(745) PE(36:1) x x 
 151 
negative 746.8/196.1 PE PE(747) PE(36:0) x x 
negative 748.8/196.1 PE PE(749) PE(38:6e)/PE(38:5p) x x 
negative 750.8/196.1 PE PE(751) PE(38:5e)/PE(38:4p) x x 
negative 752.8/196.1 PE PE(753) PE(38:4e)/PE(38:3p) x x 
negative 762.8/196.1 PE PE(763) PE(38:6) x x 
negative 764.8/196.1 PE PE(765) PE(38:5) x x 
negative 766.8/196.1 PE PE(767) PE(38:4) x x 
negative 772.8/196.1 PE PE(773) PE(38:1) x x 
negative 774.8/196.1 PE PE(775) PE(40:7e)/PE(40:6p) x x 
negative 776.8/196.1 PE PE(777) PE(40:6e)/PE(40:5p) x x 
negative 778.8/196.1 PE PE(779) PE(40:5e)/PE(40:4p) x x 
negative 788.8/196.1 PE PE(789) PE(40:7) x x 
negative 790.8/196.1 PE PE(791) PE(40:6) x x 
negative 591.6/153 PA STD PA(592) STD PA(14:0/14:0) x x 
negative 647.8/153 PA PA(648) PA(32:0) x x 
negative 671.7/153 PA PA(672) PA(34:2) x x 
negative 673.7/153 PA PA(674) PA(34:1) x x 
negative 695.8/153 PA PA(696) PA(36:4) x x 
negative 697.8/153 PA PA(698) PA(36:3) x x 
negative 699.8/153 PA PA(700) PA(36:2) x x 
negative 723.6/153 PA PA(724) PA(38:4) x x 
negative 585.6/241.1 PI STD PI(586) STD PI(8:0/8:0) STD x x 
negative 833.8/241.1 PI PI(834) PI(34:2) x x 
negative 835.8/241.1 PI PI(836) PI(34:1) x x 
negative 837.8/241.1 PI PI(838) PI(34:0) x x 
negative 857.8/241.1 PI PI(858) PI(36:4) x x 
negative 859.8/241.1 PI PI(860) PI(36:3) x x 
negative 861.8/241.1 PI PI(862) PI(36:2) x x 
negative 863.8/241.1 PI PI(864) PI(36:1) x x 
negative 865.8/241.1 PI PI(866) PI(36:0) x   
negative 883.8/241.1 PI PI(884) PI(38:5) x x 
negative 885.8/241.1 PI PI(886) PI(38:4) x x 
negative 887.8/241.1 PI PI(888) PI(38:3) x x 
negative 909.9/241.1 PI PI(910) PI(40:6) x x 
negative 911.9/241.1 PI PI(912) PI(40:5) x x 
negative 913.9/241.1 PI PI(914) PI(40:4) x x 
negative 678.6/591.6 PS STD PS(679) STD PS(14:0/14:0) x x 
negative 760.8/673.8 PS PS(761) PS(34:1) x x 
negative 762.8/675.7 PS PS(763) PS(34:0) x x 
negative 782.6/695.7 PS PS(783) PS(36:4) x x 
negative 784.8/697.8 PS PS(785) PS(36:3) x x 
negative 786.8/699.8 PS PS(787) PS(36:2) x x 
negative 788.8/701.8 PS PS(789) PS(36:1) x x 
negative 806.8/719.6 PS PS(807) PS(38:7) x x 
negative 808.8/721.6 PS PS(809) PS(38:6) x x 
negative 810.8/723.8 PS PS(811) PS(38:5) x x 
negative 812.8/725.8 PS PS(813) PS(38:4) x x 
negative 814.8/727.6 PS PS(815) PS(38:3) x x 











negative 834.8/747.8 PS PS(835) PS(40:6) x x 
negative 836.8/749.8 PS PS(837) PS(40:5) x x 
negative 838.8/751.8 PS PS(839) PS(40:4) x x 
negative 840.8/753.7 PS PS(841) PS(40:3) x x 
negative 665.6/153 PG STD PG(666) STD PG(14:0/14:0) x x 
negative 719.7/153 PG PG(720) PG(32:1) x x 
negative 721.7/153 PG PG(722) PG(32:0) x x 
negative 745.8/153 PG PG(746) PG(34:2) x x 
negative 747.8/153 PG PG(748) PG(34:1) x x 
negative 749.8/153 PG PG(750) PG(34:0) x x 
negative 773.8/153 PG PG(774) PG(36:2) x x 
negative 775.8/153 PG PG(776) PG(36:1) x x 
Sterols 
(x - indicates that the lipid was measured in the particular chapter) 
 
Mode MRM Class Sterol Species Chapter  4 
Chapter  
5-7 
positive 375.3/161.0 Sterols STD Cholesterol(d7) STD x x 
positive 369.3/161.0 Sterols Cholesterol x x 
positive 375.3/167.0 Sterols STD Cholesterol Ester(d6) STD x x 
positive 369.3/161.0 Sterols Cholesterol Ester x x 
positive 392.3/159.0 Sterols STD 7β-hydroxy-cholesterol(d7) STD x x 
positive 385.3/159.0 Sterols 7β-hydroxy-cholesterol     
positive 374.3/159.0 Sterols STD 24S-hydroxycholesterol(d7) STD x x 
positive 367.3/159.0 Sterols 24S-hydroxy-cholesterol   x 
positive 408.3/175.0 Sterols STD 7-ketocholesterol(d7) STD x x 
positive 401.3/175.0 Sterols 7-ketocholesterol     
positive 392.5/159.0 Sterols STD 22R-hydroxycholesterol(d7) STD x x 
positive 385.3/159.0 Sterols 22R-hydroxycholesterol x x 
positive 374.3/159.0 Sterols STD 7-dehydrocholesterol(d7) STD x x 
positive 367.3/159.0 Sterols 7-dehydrocholesterol x x 
positive 392.5/159.0 Sterols STD 5,6-epoxycholesterol(d7) STD x x 
positive 385.3/159.0 Sterols 5,6-epoxy-cholesterol x   
positive 391.5/227.0 Sterols STD 27-hydroxy-cholesterol(d6) STD x x 
positive 385.3/159.0 Sterols 27-hydroxy-cholesterol x x 
positive 415.5/95.1 Sterols STD lanosterol(d6) STD x x 
positive 409.7/95.1 Sterols lanosterol x   
positive 373.3/159.0 Sterols STD 25-hydroxy-cholesterol(d6) STD x x 
positive 367.3/159.0 Sterols 25-hydroxy-cholesterol     
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a Standard breakfast consisted of 1 blueberry muffin 
 
b Standard Lunch 
Energy (kcal) 507.91 kcal 
Protein (g) 16.69 g 
Total fat (g) 17.42 g 
Saturated fat (g) 7.11 g 
Dietary fibre (g) 1.56 g 
Carbohydrate (g) 71.05 g 
Cholesterol (mg) 82.08 mg 
Sodium (mg) 547.67 mg 
 
b Standard lunch consisted of scrambled egg with whole milk, butter and pepper (20.55g), 
cooked white rice (200g), 1 piece of white oven fried fish fillet and a portion of fried chye sim 
(43g).  
 
The conversion of energy and nutritional value for each standardized meal was 














a Standard Breakfast 
Energy (kcal) 248.22 kcal 
Protein (g) 3.59 g 
Total fat (g) 12.79 g 
Saturated fat (g) 7.14 g 
Dietary fibre (g) 0.63 g 
Carbohydrate (g) 29.74 g 
Cholesterol (mg) 63.63 mg 
Sodium (mg) 309.33 mg 
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Supplementary Table S3 p-value of Friedman test between the erythrocyte lipid samples 






























































































































































































































































Supplementary Table S4 Demographics of the individuals who had their erythrocytes 
analyzed using SEM. 	   Controls Patients 
N 10 10 
Gender (male/female) 7(70%)/3(30%) 7(70%)/3(30%) 
Age (years) 34.4(9.28) 30.50 (8.30) 
Ethnicity   
Chinese 10 (100%) 10 (100%) 
Non Smoker/ Smoker 8(80%)/2(20%) 8(80%)/2(20%) 
Smokers classification 	   	  
current smoker 2(20%) 2(20%) 
ex smoker 2(20%) 0(0) 
never smoked 6(60%) 8(80%) 
Daily cpz equivalents (mgs) 	   339.7(325.7)  
 
Supplementary Table S5 Comparative morphological deformities in the erythrocytes 

















Discocytes 95.04 ± 0.31 89.64 ± 0.42 <0.0001 
Multiple processes 2.10 ± 0.22 4.27 ± 0.33 <0.0001 
Knizocytes 2.67 ± 0.20 5.06 ± 0.35 <0.0001 
Dome shaped 0.16 ± 0.04 0.82 ± 0.10 <0.0001 

































Supplementary Figure S1 The analytical precision of the MS dataset in Chapter 5.  
The analytical precision of the dataset was presented as a heatmap with CVA of each lipid 
species (in percent), within each individual batch and across all two batches calculated based 
on QC samples that were periodically run together with the study samples. SE represents the 
standard error mean. Based on the diagram, the CVA within each batch ranged from 4 - 70%. 
Nonetheless, the CVA of majority of the lipid species in each batch is at an average of <10%, 
which is well within the GLP criteria. The run-to-run variation across the two batches in each 
lipid species was also determined and had an overall CVA <15% which is well within the FDA 
guideline of <20% for acceptability in analytical precision.  
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Supplementary Figure S2 Comparison of the pre-analytical and analytical precision of 
all the lipids monitored in the erythrocyte lipidome represented as CVP and CVA, 
respectively (in percent) in Chapter 5.  
It should be noted that the measure of variation due to pre-analytical precision (CVP) is 
inclusive of the contribution of CVA. As shown in the heat plot, majority of the CVP was 
similar to that of CVA thus suggesting that variability due to sample processing was kept to a 
minimal. This observation also suggests instrument imprecision as the main contributor of 
technical variation. In consequent, the measure of technical variation for the rest of the study 
assumes pre-analytical imprecision to be negligible and solely considers instrumental 
variation as measured by CVA. 
CVP!









































Supplementary Figure S3 Run-to-run analytical precision of lipid dataset across the two 
batches represented as CVA (in percent) in Chapter 5.  
Only lipid species with CVA across the two batches with an average of <20% (in accordance 
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Supplementary Figure S4 The analytical precision of the MS dataset in Chapter 6. 
The analytical precision of the dataset was presented as a heatmap with CVA of each lipid 
species (in percent). The CVA within each individual batch and across all ten batches was 
calculated based on QC samples that were periodically run together with the study samples. 
SE represents the standard error mean. Based on the diagram, the CVA within each batch 
ranged from 2 - 200%. Nonetheless, the CVA of majority of the lipid species in each batch is 
at an average of <10% thus well within the FDA guideline of <20% for acceptability in 
analytical precision. The run-to-run variation of the ten batches, as shown in the overall CVA 
of each lipid species was also determined and was observed to be higher than the inter-batch 
















































Supplementary Figure S5 Comparison of the pre-analytical and analytical precision of 
all the lipids monitored in the erythrocyte lipidome represented as CVP and CVA, 
respectively (in percent) in Chapter 6. 
 It should be noted that the measure of variation due to pre-analytical precision (CVP) is 
inclusive of the contribution of CVA. As shown in the heat plot, majority of the CVP was 
similar to that of CVA thus suggesting that variability due to sample processing was kept to a 















































































































































































































































































































































































































































































































































































Supplementary Figure S6 PCA score plots of the ten batches after LOESS correction in 
Chapter 6. 
(A-D) are the uncorrected PCA plots while (E-F) show the LOESS corrected plots. Evidently, 
LOESS correction removed the batch-to-batch variation of the datasets. ‘True’ refers to QC 
samples while ‘False’ denotes study samples. 
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